Introduction {#s1}
============

The calcium signal triggering fast synchronous secretion in chemical synapses and neuroendocrine cells is confined to nanodomains or microdomains around calcium channels ([@bib36]); it is of high amplitude, but brief duration, and calcium sensors that trigger synchronous release therefore display fast kinetics, but low affinity ([@bib41]). These sensors include synaptotagmin (syt)-1,-2 and -9 ([@bib60]). Another class of calcium sensors has high affinity and slow kinetics; they are suited to detect increases in the spatially averaged calcium concentration following stimulation. These sensors -- including Munc13 proteins -- act in preparing vesicles for later release, that is, they promote vesicle priming by stimulating SNARE-complex formation ([@bib24]; [@bib28]; [@bib29]). For some calcium sensors, it remains controversial whether they belong to one or the other class -- or to both.

A high-affinity calcium sensor in the adrenal medulla, pancreatic beta cells and central neurons is Doc2B ([@bib14]; [@bib19]; [@bib43]). Doc2 proteins are named after their double C2-domains; they lack a transmembrane domain and calcium-binding therefore leads to the protein cycling on and off the plasma membrane, dictated by the electrical activity of the cell ([@bib18]). For Doc2B, half-maximal membrane binding occurs at \~0.2 μM calcium ([@bib18]). In neurons, Doc2B stimulates spontaneous release ([@bib19]; [@bib38]). This function aligns well with the ability of Doc2B to bind to SNAREs, stimulate membrane stalk formation ([@bib8]) and SNARE-dependent membrane fusion in vitro ([@bib19]) and would be consistent with a function of Doc2B in triggering fusion, at lower calcium concentrations than syt-1,-2 and -9. This was further supported by the finding that a permanently membrane-bound Doc2B, the DN-mutant, resulted in a high and calcium-independent mini release rate ([@bib19]). However, mutation of all six Ca^2+^-coordinating aspartates created a mutant (denoted '6A'), which could not bind to Ca^2+^, but still supported spontaneous release ([@bib38]). It was instead suggested that Doc2B might perform an upstream Ca^2+^-independent function in increasing spontaneous release ([@bib38]). One group has reported that Doc2A acts as a calcium sensor involved in asynchronous release, which can also be supported by Doc2B following overexpression ([@bib62]; [@bib15]; [@bib61]). However, other groups reported no change in asynchronous release following elimination of Doc2B ([@bib19]), or all Doc2-proteins ([@bib38]). Yet another proposed function of Doc2B is to serve as a scaffold by recruiting other factors to the release machinery. Munc13-proteins bind to the MID-domain in the N-terminal tail of the protein ([@bib37]; [@bib31]), providing a mechanism to target Munc13-1 to the plasma membrane ([@bib13]). In insulin releasing β-cells, secretion was impaired in the absence of Doc2B ([@bib43]), and it was suggested that Doc2B might serve as a scaffold for Munc18-1 and Munc18c ([@bib42]).

Data obtained after knockout of Doc2B in mouse adrenal chromaffin cells showed a dual effect: the size of the Readily Releasable Pool (RRP) of vesicles was decreased -- especially during repetitive stimulation -- and the sustained component of release was potentiated ([@bib40]). Consistently, upon overexpression of Doc2B, the RRP size increased and the sustained component was inhibited. Overall, Doc2B synchronizes release with the onset of the calcium signal. Here, we addressed the question whether those roles of Doc2B represent calcium dependent or independent functions. We further investigated whether the two functions of Doc2B in chromaffin cells require interaction with other proteins. We conclude that Doc2B plays distinct Ca^2+^-independent and Ca^2+^-dependent roles in two sequential vesicle priming steps, which support the Slowly Releasable Pool (SRP) and the RRP, respectively ([@bib5]; [@bib57]; [@bib56]). The effect of Doc2B to move vesicles into the RRP requires interactions with Ca^2+^, ubMunc13-2 and SNAREs -- and the presence of syt-1.

Results {#s2}
=======

Doc2B requires synaptotagmin-1 and Munc13-2 to stimulate priming {#s2-1}
----------------------------------------------------------------

To demonstrate the role of Doc2B in chromaffin cells we first compared secretion from Doc2B knockout (KO) adrenal chromaffin cells with Doc2B KO cells overexpressing Doc2B ([Figure 1A](#fig1){ref-type="fig"}). Doc2B was expressed from a bicistronic Semliki Forest Virus construct co-expressing EGFP as an expression marker. Doc2A is not expressed in adrenal chromaffin cells ([@bib14]; [@bib40]). Secretion was elicited using calcium uncaging and monitored using capacitance measurements. Vesicle priming in chromaffin cells is calcium dependent, such that a higher \[Ca^2+^\]~i~ before stimulation increases the size of the exocytotic burst ([@bib56]). In the first set of experiments, we stimulated cells from a high basal \[Ca^2+^\]~i~ to maximize priming ([Figure 1A](#fig1){ref-type="fig"}, *insert* in top panel; 828.8 ± 24.3 nM for Doc2B KO cells, 935.7 ± 30.3 nM for KO cells overexpressing Doc2B WT). The results ([Figure 1A](#fig1){ref-type="fig"} mid panel shows the mean capacitance traces of all recorded cells) showed that expression of Doc2B had a dual effect: it increased the burst of secretion (defined as capacitance increase within 0.5 s of uncaging, [Figure 1A](#fig1){ref-type="fig"}), while it decreased sustained release (capacitance increase between 0.5 and 5 s after uncaging, [Figure 1A](#fig1){ref-type="fig"}). Because sustained release dominates at later times, total release over the course of the experiment (5 s) was reduced by Doc2B expression. Detection of liberated catecholamines was performed by amperometry, in parallel with capacitance measurements from the same cells ([Figure 1A](#fig1){ref-type="fig"}, bottom panel shows mean traces of all recorded cells). Following integration, the amperometric signal mimicked the capacitance trace, confirming those measurements and showing that the vesicles released catecholamines. However, amperometry cannot distinguish between fast and slow burst components due to the diffusional delay. As a control, we also expressed Doc2B in WT chromaffin cells (CD1 mice and -- in separate experiments -- Black6 mice), which express endogeneous Doc2B, and we found similar changes: an increase in burst release, and a decrease in the sustained component ([Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}). We conclude that overexpression of Doc2B to boost endogenous levels can be used to assay these two opposing effects of Doc2B in adrenal chromaffin cells. Previous data comparing WT to Doc2B KO cells identified consistent changes: a decrease in burst release (seen most clearly during depolarization protocols), and an increase in sustained release upon elimination of Doc2B ([@bib40]). Thus, even though overexpression using Semliki vectors boost protein levels far beyond endogenous levels, the effects on secretion are consistent with those seen in the presence of endogenous expression levels.

![Doc2B requires synaptotagmin-1 and Munc13-2 to increase the Readily Releasable Pool (RRP) size.\
(**A**) Expression of Doc2B in Doc2B knockout (KO) mouse adrenal chromaffin cells. Top panels: Intracellular \[Ca^2+^\] (mean ±SEM) after and (*insert*) shortly before Ca^2+^ uncaging (uncaging light for 1--2 ms at red arrow). Middle panel: average capacitance traces from Ca^2+^ uncaging experiments in Doc2B KO cells (magenta traces, n = 40 cells) and after overexpression of Doc2B WT in Doc2B KO cells (grey traces, n = 36 cells). Bottom panel: amperometric measurements (mean traces) from the same cells. Traces showing a release transient after the uncaging stimulus are the amperometric currents (left ordinate axes). Monotonically increasing traces display the time-integral of the amperometric current (i.e. the charge), scaled to the right ordinate axis. Note that the time-integrals display the same general shape as the capacitance traces, as expected. (**Ai**) The amplitude (mean ±SEM) of the fast burst was increased by Doc2B (\*\*\*p\<0.001, Mann-Whitney test), whereas (**Aii**) the amplitude of the slow burst component remained constant. Fast and slow burst correspond to the sizes of the RRP and the SRP, respectively. (**Aiii**) The rate of the near-linear sustained component (**D**) was strongly reduced by Doc2B (\*\*\*p\<0.001, Mann-Whitney test). (**Aiv**) The fusion time constant for the fast burst, and (**Av**) fusion time constant for the slow burst were unaffected by Doc2B. (**B**) Ca^2+^ uncaging experiment in syt-1 KO cells (n = 18) and syt-1 KO cells overexpressing Doc2B WT (n = 20). Panels (**B--Bv**) are arranged as in **A**. Doc2B expression led to a highly significant reduction in sustained release, but no significant changes in the fast or slow burst sizes. \*\*\*p\<0.001, Mann-Whitney test. (**C**) Ca^2+^ uncaging experiment in syt-7 KO cells (n = 17) and syt-7 KO cells overexpressing Doc2B WT (n = 17). Panels (**C--Cv**) are arranged as in **A**. Doc2B expression led to a significant increase in fast burst size (\*\*p\<0.01, Mann Whitney test), and a reduction in sustained release (\*\*p\<0.01, unpaired, two-tailed Student's *t* test), as in control experiments (panel A). (**D**) Ca^2+^ uncaging experiment in Munc13-2 KO cells (n = 16) and Munc13-2 KO cells overexpressing Doc2B WT (n = 18). Panels (**D--Dv**) are arranged as in **A**. All components of release were reduced by overexpression of Doc2B WT in the absence of Munc13-2 (\*\*p\<0.01, \*\*\*p\<0.001, Mann Whitney test; \# p=0.0575, unpaired two-tailed Student's t-test). The time constant of the slow component was increased (\*\*\*p\<0.001, unpaired two-tailed Student\'s t-test).](elife-27000-fig1){#fig1}

We performed kinetic analysis to quantify the changes induced by Doc2B expression in fast and slow burst secretion, which originate from the Readily Releasable vesicle Pool (RRP) and the Slowly Releasable Pool (SRP), respectively ([@bib56]; [@bib58]). These analyses showed that the fast burst amplitude -- corresponding to RRP size -- was increased by Doc2B expression ([Figure 1Ai](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1Ai,Bi](#fig1s1){ref-type="fig"}), whereas slow burst amplitude -- corresponding to SRP size -- was unchanged when expressing Doc2B in Doc2B KO cells ([Figure 1Aii](#fig1){ref-type="fig"}), or after expression of Doc2B in Black 6 WT cells ([Figure 1---figure supplement 1Bii](#fig1s1){ref-type="fig"}), although it was increased when expressing Doc2B in CD1 WT cells ([Figure 1---figure supplement 1Aii](#fig1s1){ref-type="fig"}). The sustained component was strongly reduced in all three mouse lines ([Figure 1Aiii](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1Aiii,Biii](#fig1s1){ref-type="fig"}). The time constants of fusion of fast and slow burst fusion were not significantly changed ([Figure 1Aiv,Av](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1Aiv, Av, Biv, Bv](#fig1s1){ref-type="fig"}). Thus, Doc2B has opposing effects on RRP size and sustained release, whereas the effect on the SRP differs between the two mouse lines (Black6 and CD1). Note that our KO mice are backcrossed to a Black6 background.

A promoting effect on RRP size implies that Doc2B stimulates RRP filling (priming) during period of rest (i.e. before stimulation). We next wanted to understand whether Doc2B requires the presence of other exocytotic priming proteins in the cell in order to stimulate priming, or whether it acts independently. Synaptotagmin-1 (syt-1) knockout (KO) chromaffin cells display a smaller-than-normal fast burst (RRP), whereas the slow burst is preserved ([@bib54]; [@bib32]); this slow burst depends on synaptotagmin-7 (syt-7) ([@bib50]). Overexpression of syt-1 on the wildtype background can increase the size of the RRP further ([@bib35]), indicating that syt-1 abundance controls the step converting SRP to RRP. Both Syt-1 KO and Syt-7 KO express endogenous Doc2B ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). We overexpressed Doc2B in syt-1 KO cells, and found that it did not increase the fast bursts in these cells, but it still led to a significant decrease in the sustained component ([Figure 1B,Bi--iii](#fig1){ref-type="fig"}). There was a non-significant decrease in slow burst in overexpressing cells, which might have been influenced by the reduction of the sustained component, which during kinetic analysis might 'leak into' the slow burst component. Changes in fusion time constants were not detected ([Figure 1Biv,Bv](#fig1){ref-type="fig"}). Thus, Doc2B acts upstream of or in cooperation with syt-1 to increase the RRP size, not in a redundant pathway. In syt-7 KO chromaffin cells all the components of release were depressed compared to WT cells ([@bib50]) ([Figure 1C](#fig1){ref-type="fig"}). In syt-7 KO chromaffin cells, expression of Doc2B caused an increase of the fast burst and a decrease of the sustained component ([Figure 1C,Ci--Cv](#fig1){ref-type="fig"}), indicating that Doc2B does not rely on syt-7. Amperometric measurements delivered independent evidence for the increase in burst release and decrease in sustained component upon overexpression of Doc2B in the syt-7 KO.

Munc13-proteins are the canonical priming proteins in neurons ([@bib2]) and chromaffin cells ([@bib1]), acting by opening syntaxin-1 within the confines of Munc18 ([@bib28]) to facilitate SNARE-complex assembly. ubMunc13-2 is the dominating Munc13 isoform in adrenal chromaffin cells, and in its absence the fast burst of release was reduced due to a priming defect ([@bib29]). Interestingly, expressing Doc2B WT in ubMunc13-2 KO cells not only failed to support the increase in fast burst amplitude, but led to near-abolishment of all secretory phases ([Figure 1D,Di--Dv](#fig1){ref-type="fig"}), similar to the defect seen when eliminating SNARE-proteins ([@bib47]; [@bib6]). This effect was confirmed by amperometry measurements ([Figure 1D](#fig1){ref-type="fig"}). Thus, Munc13-2 is required for the promoting functions of Doc2B on priming, and negative functions of Doc2B dominate in its absence.

Mutated Doc2B renders vesicle priming Ca^2+^-independent {#s2-2}
--------------------------------------------------------

Vesicle priming in chromaffin cells is Ca^2+^-dependent, with higher Ca^2+^ concentrations in the sub-μM range leading to a larger burst of release ([@bib5]; [@bib57]; [@bib56]). This mechanism is physiologically important, because it makes it possible for G-protein coupled receptors, which stimulate Ca^2+^-release from intracellular stores to increase \[Ca^2+^\] in the sub-µM range, to act synergistically with neuronal stimulation to strongly increase adrenaline output ([@bib52]). Since Doc2B is a priming protein with Ca^2+^-dependent trafficking, we next investigated the possibility that it might act as a Ca^2+^-sensor for vesicle priming. To this end, we mutated Doc2B's Ca^2+^-binding sites. Mutating two of the coordinating aspartate residues in the C2A-domain to asparagine (D218N/D220N, denoted DN-mutation) causes Doc2B to reside permanently at the plasma membrane ([@bib18]; [@bib14]; [@bib15]; [@bib61]; [@bib30]). Immunostainings against Doc2B and synaptobrevin-2(syb-2)/VAMP2 are shown in [Figure 2A and B](#fig2){ref-type="fig"}. The DN-mutant was expressed at similar levels as WT Doc2B ([Figure 2A,C](#fig2){ref-type="fig"}), and the vesicular marker VAMP2/synaptobrevin-2 staining also showed similar levels in separate stainings ([Figure 2B,D](#fig2){ref-type="fig"}). Inspecting the stainings, both the WT and the DN mutant appeared to be at or close to the plasma membrane, but chemical fixation can cause Ca^2+^-influx, which induces trafficking of Doc2B at the sub-μM level; thus, membrane localization cannot be assess from staining of fixed samples. Instead, we used an EGFP fusion protein and live cell confocal imaging to assess localization ([Figure 3](#fig3){ref-type="fig"}). These measurements verified previous findings and showed that Doc2B readily traffics between cytosol and plasma membrane during reversible exposure to a High-K^+^ solution ([Figure 3A--C](#fig3){ref-type="fig"})([@bib18]). In contrast, the DN-mutant was present at the membrane at higher levels than the WT protein at rest ([Figure 3A,B](#fig3){ref-type="fig"}). Nevertheless, additional trafficking of the DN-mutant to the membrane was seen during High-K^+^ exposure, due to Ca^2+^-binding to the C2B-domain ([Figure 3C](#fig3){ref-type="fig"}).

![Overexpression of Doc2B in Doc2A/B deficient chromaffin cells transfected with semliki vectors.\
(**A--B**) Typical chromaffin cells stained for (**A**) Doc2B or (**B**) VAMP2/synaptobrevin-2 to mark chromaffin granules. EGFP was co-expressed from an internal ribosome entry site (IRES) to mark semliki infection. 'Control' indicates non-infected cells. WT: wildtype Doc2B; ΔTCT: deletion of aa. 2--9 to block Tctex-1 binding; MID_mut: substitution of aa. 15--20 (QEHMAI to YKDWAF) to block Munc13 interaction; ΔMID: deletion of aa. 14--41 to block Munc13 interaction; 6A: D163,218,220,303,357,359A; DN: D218,220N, KE: K237,319E. (**C--D**) Average staining intensity ±sem for (**C**) Doc2B and (**D**) VAMP2/synaptobrevin-2 from the indicated number of cells. \*p\<0.001 (t-test for independent samples with Bonferroni correction).](elife-27000-fig2){#fig2}

![Doc2B translocates to the plasma membrane in a calcium-dependent manner.\
(**A**) Live confocal imaging experiments in CD1 mouse adrenal chromaffin cells expressing Doc2B WT, Doc2B ΔMID, Doc2B 6A or Doc2B DN fused to EGFP. Cells depolarization with High K^+^ solution (59 mM) triggers the recruitment of Doc2B WT, Doc2b ΔMID and in a lesser extent Doc2B DN to the plasma membrane. Mutations of the calcium binding residues of both C2 domains of Doc2B (Doc2B 6A) led to a permanent localization at the plasma membrane. Washing with extracellular solution (Wash) permits Doc2B WT and ΔMID to re-localize in the cytosol. Scale bar = 5 µm (**B**) Quantification of Doc2B intensity (ratio total intensity/cytosol intensity) during live imaging experiment. Cells were imaged at resting and after 1 to 5 min stimulation (high K+) every minute, and then washed with extracellular solution and imaged every minute for 5 min. (**C**) Quantification of the plasma membrane recruitment of doc2B WT and mutants after 1 min stimulation with high K^+^ solution (Difference in ratio \[total fluorescence intensity/cytosol fluorescence intensity\] at 1 min compared to resting) showing that only Doc2b 6A does not traffic (n cells: Doc2B WT: 4; Doc2B 6A: 5; Doc2b DN: 11; Doc2B ΔMID: 8. Panel C: One-sample t-test comparing the difference in fluorescence ratio to zero; \* p-value\<0,05; \*\*\* p-value\<0.001).](elife-27000-fig3){#fig3}

For physiological measurements, we expressed the DN-mutant and EGFP separately from a bicistronic message ([Figure 4](#fig4){ref-type="fig"}). To specifically test Ca^2+^-dependent priming, we adjusted the Ca^2+^ concentration of our pipette solution to either \~200 nM ([Figure 4A](#fig4){ref-type="fig"}), or to \~900 nM ([Figure 4G](#fig4){ref-type="fig"}). Final adjustments (increases) in the \[Ca^2+^\] were achieved using monochromator light (which was used simultaneously to monitor \[Ca^+2^\]) to uncage some of the Ca^2+^-cage \~20 s before stronger stimulation using a flash UV-lamp to probe secretion itself ([@bib56]). When we carried out Ca^2+^ uncaging experiments from a low resting \[Ca^2+^\]~i~ (\~200 nM, [Figure 4A](#fig4){ref-type="fig"}) expression of Doc2B WT caused an increase in slow burst release and a decrease in the sustained release rate ([Figure 4A--D](#fig4){ref-type="fig"}). Strikingly, when expressing the Doc2B DN-mutation, the burst was potentiated even more (orange curve, [Figure 4A](#fig4){ref-type="fig"}). The potentiation was seen both in the fast and the slow burst components ([Figure 4B,C](#fig4){ref-type="fig"}). In experiments with a high basal \[Ca^2+^\]~i~ ([Figure 4G](#fig4){ref-type="fig"}), both Doc2B KO cells and KO cells overexpressing Doc2B responded with a larger exocytotic burst (compare secretion within the first 0.5 s after the stimulation in [Figure 4A and G](#fig4){ref-type="fig"}), showing that calcium-dependent priming was successfully induced. However, under these conditions, the responses of DN-mutant cells were now indistinguishable from the WT, for all secretory phases ([Figure 4G--J](#fig4){ref-type="fig"}). At our high basal \[Ca^2+^\]~i~ condition (\~900 nM), Doc2B WT will be fully Ca^2+^-saturated and membrane localized ([@bib18]). Strikingly, when comparing the burst amplitude (fast + slow burst) in the DN-mutation with the WT, it is clear that the DN-mutation rendered burst amplitude independent of preflash-\[Ca^2+^\]~i~ ([Figure 4M](#fig4){ref-type="fig"}). This indicates that Ca^2+^ binding to WT Doc2B drives priming of new vesicles, or that this reaction is bypassed when Doc2B is permanently localized at the plasma membrane (see Figure 10 and Discussion). Therefore, the DN-mutant is a gain-of-function mutant in chromaffin cells when studied from a low basal \[Ca^2+^\]. Kinetic analysis indicated that the DN-mutant decreased the time constant for fast fusion ([Figure 4K](#fig4){ref-type="fig"}), perhaps indicating a separate property of this protein. The inhibitory effect was unchanged by the DN-mutation, whether probed from high or low basal \[Ca^2+^\]~i~ ([Figure 4D,J](#fig4){ref-type="fig"}). Thus, Doc2B has separate positive and negative effects on secretion.

![The Doc2B DN-mutant (D218,220N) supports maximal vesicle priming independently of the Ca^2+^ level.\
(**A-F**) at low basal (preflash) calcium, the DN-mutant supports more secretion than WT Doc2B. (**A**) Ca^2+^ uncaging experiments in Doc2B KO cells (n = 12), Doc2B KO cells overexpressing Doc2B WT (n = 19) and Doc2B KO cells overexpressing Doc2b DN (n = 20 cells). Top panel shows the average (±SEM) post-flash \[Ca^2+^\]~i~ measured by microfluorimetry; inset shows the pre-flash \[Ca^2+^\]~i~. Bottom panel shows the changes in cell membrane capacitance (mean traces for all cells). (**B--F**) Kinetic analysis revealed that both the fast and slow bursts were larger upon overexpression of Doc2B DN than of Doc2B WT, leading to a gain of function phenotype at low basal cell calcium. The sustained component was similarly decreased by overexpression of wildtype and DN-mutated Doc2B (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, Dunn's multiple comparison test). (**G**), similar experiment to (**A**) but in high basal pre-flash Ca^2+^ (Doc2B KO, n = 20 cells; Doc2B KO expressing Doc2B WT, 20 cells; Doc2B KO expressing Doc2B DN, 32 cells). (**H--L**) Kinetic analysis shows that overexpression of either Doc2B DN or Doc2B WT causes a similar increase in the fast burst. Similar to the low preflash \[Ca^2+^\]~i~ experiment, the sustained component was decreased to the same levels by overexpression of both proteins. (**K**) Overexpression of Doc2B DN caused a significant acceleration of the fast burst fusion kinetics. (**M**) Plot of the total burst size (fast + slow) as a function of the basal cell calcium reveals that Doc2B DN supports maximal LDCV priming irrespective of the cell Ca^2+^. \*p\<0.05, \*\*\*p\<0.001; Dunn's multiple comparison test.](elife-27000-fig4){#fig4}

The 6A-mutation, which includes aspartate-to-alanine mutations of six key Ca^2+^-binding aspartate residues, three in each C2-domain (C2A: D163A/D218A/D220A, C2B: D303A/D357A/D359A) blocks Ca^2+^ binding to both C2-domains ([@bib38]). Although the 6A-mutant cannot bind to Ca^2+^, it was able to rescue the normal mEPSC frequency in cultured neurons ([@bib38]). This finding was used to argue that Doc2B has calcium-independent upstream effects on miniature release. Here, using live cell imaging of a Doc2B(6A)-EGFP fusion protein we showed that the 6A-mutant localizes permanently to the plasma membrane in excess of the WT protein, and it does not traffic in response to depolarization ([Figure 3A,B,C](#fig3){ref-type="fig"}). Similar results were previously reported using a quadruple aspartate-to-asparagine mutation in C2A/B ([@bib15]).

When expressed from a bicistronic message, the 6A-mutant reached protein levels similar to those of WT Doc2B ([Figure 2A--D](#fig2){ref-type="fig"}). From low basal \[Ca^2+^\]~i~, this mutation caused a significant increase in the slow and fast burst of release ([Figure 5A,B](#fig5){ref-type="fig"}). However, from high basal \[Ca^2+^\]~i~, the fast burst of release remained unchanged compared to the Doc2B KO cells ([Figure 5G,H](#fig5){ref-type="fig"}). When plotting the burst size as a function of basal \[Ca^2+^\]~i~, cells expressing the 6A-mutation displayed a calcium-independent burst size, intermediate between the bursts supported by Doc2B WT at low and high basal \[Ca^2+^\]~i~ ([Figure 5M](#fig5){ref-type="fig"}). The invariance of the burst size with respect to basal \[Ca^2+^\]~i~ again shows that membrane localization of Doc2B occludes Ca^2+^-dependent priming. However, the 6A-mutant is not quite as efficient as the fully Ca^2+^-loaded WT Doc2b-protein -- or the DN-mutant -- since the maximal level of priming that it supports is smaller than after WT rescue, which is due to the inability to increase RRP size at high basal \[Ca^2+^\]~i~.

![Mutation of the Ca^2+^binding sites of Doc2B leads to permanent membrane localization and Ca^2+^-independent priming.\
(**A-F**) When stimulated from low basal calcium, the Ca^2+^-binding mutant Doc2B 6A supports more secretion that Doc2B WT. (**A**) Ca^2+^ uncaging in Doc2b KO cells (n = 23), KO cells overexpressing Doc2B WT (n = 19) and KO cells overexpressing Doc2B 6A (n = 18). Panels are arranged as in [Figure 4](#fig4){ref-type="fig"}. (**B--F**) Kinetic analysis revealed that the fast burst was increased more by overexpression of Doc2B 6A than by Doc2B WT, showing a gain of function of the 6A mutant at low basal cell calcium. The sustained component was similarly decreased by overexpression of either protein. \*p\<0.05, \*\*\*p\<0.001; Dunn's multiple comparison test. (**G**) similar experiment to (**A**) but stimulated from high basal pre-flash \[Ca^2+^\]~i~ (Doc2B KO, n = 25 cells; Doc2B WT, n = 21 cells; Doc2B 6A, n = 22 cells). (**H--L**) Kinetic analysis shows that overexpression of Doc2B WT caused a marked increase in the fast burst while Doc2B 6A did not, demonstrating a loss of function when studied from a high basal \[Ca^2+^\]. Similar to the low \[Ca^2+^\]~i~ experiment, the sustained component was decreased to the same levels by overexpression of both proteins. \*p\<0.05, Tukey's multiple comparison test; \*\*\*p\<0.001, Dunn's multiple comparison test. (**M**) Plot of the total burst size (fast + slow) as a function of the basal cell calcium reveals the Ca^2+^-independent priming reaction in the presence of the 6A mutant.](elife-27000-fig5){#fig5}

Half-maximal trafficking of Doc2B to the plasma membrane requires \~200 nM Ca^2+^ ([@bib18]), which coincides with resting \[Ca^2+^\] in the experiments in [Figure 3A and B](#fig3){ref-type="fig"}. Due to the finite affinity of our calcium cage, nitrophenyl-EGTA, which has a K~d~ of 80 nM ([@bib12]) it was not feasible to conduct calcium uncaging experiments from even lower basal \[Ca^2+^\]~i~. This would cause Ca^2+^ to dissociate from the cage before uncaging, leaving the unbound cage as an additional Ca^2+^-buffer that would prevent increases in \[Ca^2+^\]. Instead, we probed the DN-mutant using a depolarization protocol and a pipette solution including 0.5 mM EGTA without added Ca^2+^ ([Figure 6](#fig6){ref-type="fig"}). It is commonly assumed that six brief (10 ms) depolarizations elicit the fusion of the Immediately Releasable Pool (IRP), which are RRP-vesicles co-localized with Ca^2+^-channels, whereas four subsequent longer (100 ms) depolarizations fuse the entire RRP ([@bib55]). We compared Doc2B KO cells expressing Doc2B WT and Doc2B DN. The depolarization protocol caused a moderate increase in \[Ca^2+^\]~i~, to \~2 μM in cells expressing either construct ([Figure 6A](#fig6){ref-type="fig"}). The modest increase in \[Ca^2+^\]~i~ is due to the strong inhibition of Ca^2+^-channels induced by Doc2B overexpression in chromaffin cells ([@bib53]). Therefore, these data cannot be directly compared to findings in Doc2B KO or WT cells ([@bib40]). The DN-mutant did not induce any significant increase in IRP size over Doc2B WT ([Figure 6A--B](#fig6){ref-type="fig"}), but the capacitance after four long depolarizations was significantly increased ([Figure 6A,C](#fig6){ref-type="fig"}; we denote the increase 'RRP' for the sole reason that it was comparable to the fast burst measured by Ca^2+^ uncaging in [Figure 4A--B](#fig4){ref-type="fig"}). When repeating the protocol (6 + 4 depolarizations), the effect of the DN mutation on 'RRP' size was largest in the first two trials and subsided thereafter as the cells underwent secretory run-down ([Figure 6D](#fig6){ref-type="fig"}). These experiments show that the DN-mutation specifically increased the RRP size, but not the IRP.

![The Doc2B DN-mutant promotes the filling of the Readily Releasable vesicle Pool (RRP), but not the Immediately Releasable Pool (IRP).\
(**A**) A depolarization protocol, consisting of 6 brief (10 ms) and four long (100 ms) depolarizations from −70 mV to +20 mV, was repeated a total of 5 times (trials 1--5), separated by 60 s recovery periods. Only the first trial is depicted. A pipette solution with no added calcium and containing 0.5 mM EGTA was used (n = 21 cells for Doc2B WT; n = 22 cells for Doc2B DN). Top panel shows average (±SEM) \[Ca^2+^\]~i~. Middle panel shows the changes in cell membrane capacitance and bottom panel shows the integrated amperometric current (mean traces for all cells). (**B**) The size of the Immediately Releasable Pool (IRP) was not significantly affected by overexpression of Doc2B DN while (**C**) the size of the RRP was significantly enhanced by the Doc2B DN mutant, compared to Doc2B WT. (**D**), Plot of the mean (±SEM) RRP size over the five trials - the responses decrease because of secretory run-down. \*p\<0.05, \*\*\*p\<0.001; unpaired, two-tailed Student's t-test.](elife-27000-fig6){#fig6}

Overall, we conclude from these experiments that Doc2B is a calcium-dependent priming protein acting to increase the size of the secretory burst (consisting of the RRP and the SRP vesicles), and calcium-dependent priming can be occluded by mutations at the Ca^2+^- and phospholipid-binding interface within its C2 domains. However, the decrease of the sustained component is unchanged by mutating the Ca^2+^ binding sites of Doc2B and must, therefore, represent a distinct function of Doc2B.

SNARE interactions are necessary for the stimulation of priming by Doc2B {#s2-3}
------------------------------------------------------------------------

The poly-lysine stretch on the C2B-domain of syt-1 mediates the interaction with SNAREs and PI(4,5)P~2~ ([@bib3]; [@bib44]), and the positive charge is important for triggering release ([@bib23]). The Doc2B protein contains a similar polylysine stretch at its C2B domain, and also a smaller stretch of basic residues on the C2A domain. Mutating a lysine to glutamate in each C2 domain creates the KE-mutant (K237E/K319E), which was previously shown to display a profound loss of binding to the SNARE-complex, while retaining Ca^2+^-dependent binding to liposomes ([@bib19]). We recently found that Doc2B overexpression in adrenal chromaffin cells causes an increase in syntaxin-1 immunoavailability, due to the recruitment of syntaxin-1 from plasma membrane clusters ([@bib53]). We therefore stained for syntaxin-1 after expression of Doc2B WT and Doc2B KE in adrenal chromaffin cells ([Figure 7A](#fig7){ref-type="fig"}). Using expression of Botulinum Toxin C, we previously demonstrated that this staining is specific for syntaxin-1 ([@bib53]). The results indeed showed that syntaxin-1 staining was more intense after expressing Doc2B WT or Doc2B DN ([Figure 7B](#fig7){ref-type="fig"}), whereas expression of Doc2B KE did not change syntaxin-1 staining intensities, consistent with the loss of SNARE binding by this mutation.

![SNARE-binding of Doc2B is required for boosting the RRP, but not for inhibiting the sustained phase.\
(**A**) Fixed and Immunostained wildtype chromaffin cells stained against syntaxin-1. (**B**) Quantification of the intensity of syntaxin-1 staining shows that expression of Doc2B WT (n = 12 cells) lead to an increase in intensity compared to non-expressing control cells ('Uninf', n = 11). The KE mutation (K237,319E; n = 15) did not significantly affect syntaxin-1 staining, whereas the DN mutant increased staining (n = 12). \*\*\*p\<0.001, Dunn's multiple comparison test. (**C**) Ca^2+^ uncaging experiment in Doc2B KO cells overexpressing Doc2B WT (n = 16) or Doc2B KE (K237,319E; n = 19). Recordings from another experiment in uninfected Doc2B KO cells (pink; same data as in [Figure 9](#fig9){ref-type="fig"}) are shown in parallel (n = 25); (**D-H**) Kinetic analysis of the capacitance traces. The size of the fast burst upon Doc2B KE overexpression was similar to Doc2B KO cells and smaller that in cells overexpressing Doc2B WT (**D**) while the slow burst showed a tendency for reduced size (**E**). The sustained phase was similarly affected by expression of either Doc2B KE or Doc2B WT (**F**). No differences were identified in the release time constants (**G,H**). \*p\<0.05, \*\*\*p\<0.001; One-way ANOVA with Tukey\'s multiple comparison test.](elife-27000-fig7){#fig7}

Upon expression in Doc2B KO chromaffin cells (expression level in [Figure 2](#fig2){ref-type="fig"}), the Doc2B KE-mutant failed to support the increase in fast burst release seen upon expression of the WT protein ([Figure 7C--D](#fig7){ref-type="fig"}). However, the sustained component was depressed by the KE-mutant to similar levels as by the WT protein ([Figure 7F](#fig7){ref-type="fig"}), while the kinetics of fusion were unchanged ([Figure 7G--H](#fig7){ref-type="fig"}). Therefore, we conclude that SNARE interaction is necessary for the ability of Doc2B to increase the RRP. This agrees with previous data obtained for overexpressed Doc2A in PC12 cells ([@bib49]). We cannot, however, rule out the alternative that Doc2B:PI(4,5)P~2~ interactions could drive this function. In syt-1, lysines can interact alternatively with SNAREs or PI(4,5)P~2~ ([@bib7]; [@bib39]; [@bib64]; [@bib51]), and recently it was found that K319 in Doc2B interacts with plasma membrane PI(4,5)P~2~ ([@bib30]).

The dynein light chain Tctex-1 was identified as a Doc2-interacting partner in a yeast two-hybrid screen using the N-terminal region of Doc2A as a bait ([@bib34]). Both Doc2A and Doc2B interact with tctex-1, and the interaction site maps to the first eight amino acids ([@bib37]). In an attempt to identify the molecular background for the inhibitory function of Doc2B on vesicle priming during sustained Ca^2+^ elevation, we performed rescue experiments with a Doc2B mutant, where amino acids 2--9 were deleted (ΔTCT). The ΔTCT-mutant was expressed similarly to WT Doc2B ([Figure 2](#fig2){ref-type="fig"}) and rescued the burst of secretion (secretion within 0.5 s) almost as well as the WT Doc2B ([Figure 8A](#fig8){ref-type="fig"}). No significant differences between the Doc2B ΔTCT and Doc2B WT were identified ([Figure 8A--C](#fig8){ref-type="fig"}). The ΔTCT mutant also still recapitulated the inhibitory function of Doc2B on the sustained component of release ([Figure 8D](#fig8){ref-type="fig"}), which, therefore, does not depend on binding to tctex-1.

![A Doc2B mutant lacking the binding sequence for Tctex-1 (Doc2BΔTCT) supports normal secretion.\
(**A**) Ca^2+^ uncaging experiment in Doc2B KO cells (n = 13) and KO cells overexpressing Doc2B WT (n = 15) or Doc2BΔTCT (n = 14). (**B--F**) Kinetic analysis revealed that both vesicle pool sizes and kinetics of release were not significantly different between Doc2B WT and Doc2BΔTCT. \*p\<0.05; \*\*\*p\<0.001, Dunn's multiple comparison test.](elife-27000-fig8){#fig8}

The MID-domain is essential for both positive and negative functions of Doc2B {#s2-4}
-----------------------------------------------------------------------------

Both Doc2A and Doc2B interact with Munc13-1 through the Munc13 Interacting Domain (MID), which is located near the N-terminal end of Doc2B, encompassing amino acids 14 to 38 (sequence in Doc2B: see [Figure 9A](#fig9){ref-type="fig"})([@bib37]). Due to the MID domain Doc2B can recruit Munc13-1 to the membrane ([@bib13]). Both the MID domain in Doc2B and the C1 domain of Munc13-1 are required for that trafficking event ([@bib13]). Conversely, Munc13-1 might traffic to the plasma membrane by binding to phorbol esters through its C1 domain, bringing Doc2B along ([@bib11]); however, this has recently been questioned ([@bib13]). Overall, the effects of Doc2B on priming might depend on interactions with Munc13 proteins, as already indicated by the lack of a positive priming effect when expressing Doc2B in Munc13-2 KO cells ([Figure 1D](#fig1){ref-type="fig"}).

![The MID-domain is required for both positive and negative functions of Doc2B in vesicle priming.\
(**A**) Domain structure of mouse Doc2B. C2A and C2B are the two C2-domains. The MID-domain encompasses amino acids 14--38. We mutated the N-terminal part of the MID-domain (MID_mut, ([@bib31])), or deleted it entirely (deletion of amino acids 14--41: ΔMID). (**B**) Ca^2+^ uncaging experiment in Doc2B KO cells (n = 25) and KO cells overexpressing Doc2B WT (n = 26) or Doc2B MID_mut (n = 26). (**Bi-Bv**) Kinetic analysis showed that mutating a stretch of the Doc2B MID domain abolishes the facilitating effect that Doc2B WT has in potentiating the RRP size (i.e. the size of the fast burst) (**Bi**) while causing a similar reduction in the rate of sustained release as the wildtype protein (**Biii**). (**C**), Full deletion of the Munc13-interacting domain of Doc2B (amino acids 14--41; Doc2B ΔMID) interferes with the function of Doc2B in both the fast burst and the sustained phase of release. Ca^2+^ uncaging experiment in Doc2B KO cells overexpressing Doc2B WT (n = 18) or Doc2B ΔMID (n = 20). (**Ci-Cv**) Kinetic analysis showing that removal of the full MID region of Doc2b interferes both with the promoting action on the filling of the fast pool of vesicles (**Ci**) and alleviates the suppression of the sustained phase of release caused by Doc2B WT overexpression (**Ciii**). The data from recordings of uninfected Doc2B KO cells used in panels C is the same as the one in panels B. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001; Dunn's multiple comparison test.](elife-27000-fig9){#fig9}

To test for this possibility, we first used a mutation (MID_mut) of the MID-domain ([Figure 9A](#fig9){ref-type="fig"}), which was previously shown to eliminate the Doc2-Munc13 interaction in a cell-free pull-down assay, and to block synaptic transmission upon infusion into cholinergic synapses ([@bib31]). This mutant does not co-translocate to the plasma membrane after phorbol ester stimulation of Munc13, but still translocates after Ca^2+^ stimulation of Doc2b ([@bib17]). Expression of the MID_mut in Doc2B KO chromaffin cells (expression level in [Figure 2](#fig2){ref-type="fig"}) showed that this mutation did not support an increase in the fast burst (RRP) of release, as seen in parallel experiments after expression of Doc2B WT ([Figure 9B](#fig9){ref-type="fig"}), indicating that the MID domain is necessary for this function. However, sustained secretion was still suppressed ([Figure 9Biii](#fig9){ref-type="fig"}), and the fusion kinetics were unaffected ([Figure 9Biv--Bv](#fig9){ref-type="fig"}). Therefore, the mutation shows -- like the KE-mutation and the Ca^2+^-ligand mutations -- that the positive and negative functions of Doc2B can be separated by mutation.

The lack of an effect of the MID_mut on sustained release was puzzling, since so far it had been assumed that Munc13 binding is a prerequisite for the function of Doc2A/B in secretion (but see \[[@bib15]\]). Therefore, we decided to remove the entire MID domain, through the deletion of amino acids 14--41 ([Figure 9A](#fig9){ref-type="fig"}, Doc2B ΔMID). Importantly, this mutation was expressed at levels similar to WT protein and did not change the staining for the vesicular marker syb-2 ([Figure 2A--D](#fig2){ref-type="fig"}). Using an EGFP-fusion construct we verified that Doc2B ΔMID trafficked reversibly to the membrane indistinguishable from the WT protein when expressing chromaffin cells were exposed to High-K^+^ ([Figure 3A--C](#fig3){ref-type="fig"}). This further shows that the C2-domains are correctly folded in this mutant. Strikingly, expression of the ΔMID mutant in Doc2B KO cells led to partial recovery of the sustained component ([Figure 9Ciii](#fig9){ref-type="fig"}), which reached 42.7 ± 6.7 fF/s whereas expressing Doc2B WT depressed the sustained component to 13.3 ± 2.2 fF/s. Consistent with the results obtained with the mutated MID, the ΔMID also did not support the fast burst amplitude seen with Doc2B WT ([Figure 9Ci](#fig9){ref-type="fig"}). Although a sustained release rate of 42 fF/s is quite typical for WT chromaffin cells, Doc2B KO cells display on average higher rates (60--70 fF/s; [Figure 9Ciii](#fig9){ref-type="fig"}), which indicates that other regions outside the MID domain also contribute to the inhibitory effect. Together with the findings above that the negative effects of Doc2B on secretion entirely dominate in the Munc13-2 KO chromaffin cells ([Figure 1D](#fig1){ref-type="fig"}), this shows that the negative function of Doc2B on release requires the MID-domain, but not Munc13-2 (see also Discussion).

Discussion {#s3}
==========

In chromaffin cells, Doc2B has dual effects: it stimulates the size of the RRP from rest by boosting priming, but it inhibits priming/fusion during sustained Ca^2+^-elevations, leading to a shallower sustained release component. Thus, Doc2B joins the ranks of a number of exocytotic proteins -- including complexin, syts and Munc18s -- that have positive and negative effects on different phases of release. Here, we have dissected the involvement of the different Doc2B effectors in this phenotype. Cross-rescue showed that syt-1 and ubMunc13-2 are required for the overall stimulating effect on priming, whereas syt-7 is dispensable. Even in the absence of syt-1 or syt-7, an inhibitory function of Doc2B was seen, and inhibition dominated in the absence of Munc13-2. Mutagenesis showed that interactions with SNAREs, Munc13, and Ca^2+^ are involved in the positive effects of Doc2B on priming, whereas they were not required for the inhibitory function. Thus, the stimulatory and inhibitory effects of Doc2B can be separated by mutation. This rules out that the stimulatory effect on RRP size could be a secondary effect of the inhibition of sustained release, which in principle could lead to a larger RRP by preventing loss of vesicles.

Strikingly, both the DN and 6A mutations rendered the exocytotic burst size independent of basal \[Ca^2+^\]~i~. With the DN mutation, the primed vesicle pools attained their maximal size irrespective of basal \[Ca^2+^\]~i~, occluding Ca^2+^-dependent priming ([@bib5]; [@bib56]), whereas -- with the 6A mutation -- the RRP size was intermediate, but calcium-independent. The increase in secretion induced by the DN-mutant was previously reported by [@bib14], who used expression in WT mouse chromaffin cells; here we show by direct comparison to the wildtype protein in a rescue setting that the DN-mutation renders overall priming calcium-independent. Where the RRP was increased, the IRP was not significantly affected by the DN-mutation ([Figure 6](#fig6){ref-type="fig"}). The reason for this is unknown, but the IRP forms a subpool of the RRP ([@bib55]), which contains vesicles close to Ca^2+^-channels. Other factors (for instance the number or availability of Ca^2+^-channels) might therefore limit the size of the IRP.

The DN-mutation is situated in the C2A-domain ([@bib18]), whereas the C2B-domain also contributes essentially to Ca^2+^-induced membrane trafficking ([@bib16]; [@bib61]). The finding that the DN-mutant (and other neutralization of the Ca^2+^-binding ligands in the C2A-domain \[[@bib15]\]) lead to permanent membrane anchoring can be rationalized from the reduced electrostatic repulsion between the DN-mutant and negatively charged membrane phospholipids (phosphatidylserine and PI(4,5)P~2~), in the presence of an affinity for the membrane via the C2B-domain. Indeed, recent data show that membrane binding of both WT Doc2B and DN-mutant requires PI(4,5)P~2~ at the plasma membrane ([@bib30]). Thus both Ca^2+^-bound Doc2B WT and the DN-mutant localize to similar PI(4,5)P~2~ containing domains on the plasma membrane.

Whereas mutation of the coordinating aspartates in Doc2B (either DN or 6A mutation) renders vesicle priming Ca^2+^-independent, priming is still Ca^2+^-dependent in the absence of Doc2B (comp. [Figure 4A and G](#fig4){ref-type="fig"}), as noted before ([@bib40]). Therefore, the mutated Doc2B occludes an endogenous Ca^2+^-dependent priming factor. To gain further insight into the function of Doc2B in different priming steps, we considered the 3-pool model for exocytosis, where the RRP is refilled reversibly from the SRP, and the SRP in turn is refilled reversibly from a Depot pool (which may or may not be docked, [Figure 10](#fig10){ref-type="fig"}). In this model, the overall Ca^2+^-dependence of the burst size is due to a Ca^2+^-dependence of the transition between Depot and SRP (called *priming 1*, [Figure 10](#fig10){ref-type="fig"}) ([@bib56]; [@bib58]), which indirectly affects also the RRP. In our previous work ([@bib40]) we concluded that Doc2B acts primarily on the interconversion between SRP and RRP vesicles (*priming 2* in [Figure 10](#fig10){ref-type="fig"}). Therefore, in the Doc2B KO, the burst size (SRP + RRP) is still Ca^2+^-dependent ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"} and \[[@bib40]\]). By assuming that the steady state has been obtained before we uncage calcium, we are able (from the data in [Figure 4](#fig4){ref-type="fig"}) to calculate the ratios k~1~\[Depot\]/k~-1~ and k~2~/k~-2~, which are the overall propensities of *priming 1* and *priming 2* to drive priming forward, and compare them between genotypes ([Figure 10](#fig10){ref-type="fig"}, [Figure 10---source data 1](#fig10sdata1){ref-type="supplementary-material"}). We considered the effect of having the Doc2B protein present at \~200 nM Ca^2+^ ([Figure 10A](#fig10){ref-type="fig"}), and the effect of raising pre-stimulation \[Ca^2+^\]~i~ from \~200 nM to \~800 nM ([Figure 10B](#fig10){ref-type="fig"}). The conclusion is that Doc2B acts on both priming steps, but in different ways: it acts on *priming 2* at higher \[Ca^2+^\] ([Figure 10B](#fig10){ref-type="fig"}) to drive vesicles to the RRP ([@bib40]), but at low \[Ca^2+^\] it acts to drive *priming 1* forward ([Figure 10A](#fig10){ref-type="fig"}). This can be appreciated directly from the data by noting the large increase in SRP size in [Figures 4C](#fig4){ref-type="fig"} and [5C](#fig5){ref-type="fig"} when expressing Doc2B or its mutants and probing from low basal \[Ca^2+^\]. The effect on *priming 1* is even larger for the DN mutant than for the WT protein. The result of the upstream action is that *priming 1* loses some or (in the DN mutant) all of its Ca^2+^-sensitivity, and indeed, the Ca^2+^-sensitivity of *priming 1* is even higher in the total absence of Doc2B than in the presence of WT Doc2B ([Figure 10B](#fig10){ref-type="fig"}). Most likely there is competition between Doc2B and the upstream Ca^2+^-dependent priming sensor for *priming 1* ([Figure 10C](#fig10){ref-type="fig"}), and this is affected by mutation and probably by the relative abundance of the two sensors near the membrane. The physiological relevant function of the Doc2B protein can be appreciated from the fact that in the Doc2B KO, Ca^2+^ suppresses the transition from the SRP into the RRP, whereas in the presence of Doc2B, this transition is stimulated by Ca^2+^ ([Figure 10B](#fig10){ref-type="fig"}). Thus, the upstream Ca^2+^-sensor, when left to its own devices, would push vesicles effectively into the SRP, but the transition into the RRP would be inhibited. Doc2B, on the other hand, can prime vesicles further into the RRP by Ca^2+^-binding. Strikingly, another conclusion is that only the WT protein and the DN-mutant can push the vesicles into the RRP at higher \[Ca^2+^\] -- the 6A-mutant is not able to do that ([Figure 5H](#fig5){ref-type="fig"}) - which identifies Ca^2+^-binding to the C2B-domain as the decisive event for priming 2 ([Figure 10C](#fig10){ref-type="fig"}). The identity of the upstream Ca^2+^-dependent priming sensor acting on *priming 1* cannot be identified from this work, but candidates are synaptotagmin-7 ([@bib25]) and Munc13 isoforms ([@bib65]; [@bib24]).

![Dissecting the effect of Doc2B on two sequential priming steps.\
(**A**) Chromaffin cells feature two sequential priming steps: *priming 1*, which recruits vesicles to the SRP, and *priming 2*, which recruits them to the RRP. At equilibrium, the overall propensity for forward priming is k~1~\[Depot\]/k~-1~ and k~2~/k~-2~, respectively (see Materials and methods). Shown is the multiplicative effect of expressing Doc2B WT and DN mutant on *priming 1* and *priming 2* propensities at low \[Ca^2+^\]. Both proteins stimulate *priming 1*, but inhibit *priming 2*. It has been proposed that SRP-vesicles fuse directly ([@bib56]), or, as indicated here, that they mature to RRP-vesicles before they fuse ([@bib58]); the experiments we present here do not distinguish between two possibilities, but see ([@bib58]). (**B**) The effect of increasing \[Ca^2+^\] from 200 to \~ 800 nM, in the Doc2B KO, or after expression of Doc2B WT or DN. Ca^2+^ stimulates *priming 1* strongly in the Doc2B KO, but inhibits *priming 2*, whereas with Doc2B, *priming 2* is stimulated by Ca^2+^. (**C**) Overall model for the effect of Doc2B on *priming 1* and *priming 2*. Doc2B (and the DN and 6A mutants) stimulates *priming 1*, but also occludes its Ca^2+^-dependence, presumably by inhibiting or competing with another Ca^2+^-dependent priming protein (upstream priming sensor) that normally acts at *priming 1*. Ca^2+^ increases the effect of Doc2B on priming 2; this effect is seen also in the DN-mutant, but not in the 6A-mutant; therefore, it depends on Ca^2+^ binding to the C2B-domain.\
10.7554/eLife.27000.014Figure 10---source data 1.Values for pool sizes and *priming 1* and *priming 2* propensity from experiments in Doc2B KO, and after overexpression of Doc2B WT and DN-mutant (see also [Figure 4](#fig4){ref-type="fig"}).The propensity for upstream priming, *priming 1*, k~1~\[Depot\]/k~-1~, is simply equal to the slow burst (SRP) size, whereas the propensity for *priming 2*, k~2~/k~-2~, is equal to the ratio between fast and slow burst (RRP/SRP). To determine the effect of increasing basal \[Ca^2+^\] from \~200 nM to \~800 nM, we calculated the ratio of the propensities between Ca^2+^ concentrations for a given genotype (two columns on the right). To calculate the effect of expressing Doc2B and the Doc2B DN mutant at \~200 nM \[Ca^2+^\] we formed the ratio of the propensities between expressed and KO cells for a given \[Ca^2+^\] (six bottom rows).](elife-27000-fig10){#fig10}

At least two different -- but nonexclusive -- ideas for the action of Doc2 proteins in exocytotic processes have been put forward. The first idea is that Doc2 proteins participate in a direct capacity during the fusion process itself, by triggering Ca^2+^-dependent lipid insertion of its C2 domains, leading to membrane buckling/distortion, which assists in SNARE-dependent membrane fusion -- that is, a function akin to that often ascribed to syts. This notion has support in the observation that Doc2 proteins can accelerate membrane fusion in vitro between populations of liposomes carrying nothing but reconstituted SNAREs ([@bib19]; [@bib62]; [@bib63]; [@bib15]). The other idea is that Doc2 serves mainly as a recruitment scaffold, which brings other factors to the membrane -- or to the SNAREs, since SNARE-binding is needed ([@bib49]) (and our [Figure 7](#fig7){ref-type="fig"}) -- leading to more indirect, that is, more upstream, effects on fusion. This model has indirect support through the ability of a MID-domain peptide to interfere with synaptic transmission ([@bib31]), and by the observation of Doc2B-dependent Munc13-1 recruitment ([@bib13]). Munc13-1, in turn, might have direct effects on the fusogenicity of vesicles via SNARE-assembly ([@bib28]), or by modulating the size of the fusion barrier ([@bib4]). In pancreatic beta cells, a function of Doc2B as a scaffolding platform for Munc18 proteins has been identified ([@bib20]; [@bib42]).

Our data obtained in adrenal chromaffin cells add several lines of support to a more indirect mode of Doc2B action: first, in cross-rescue experiments, Doc2B cannot stimulate release in the absence of syt-1, the fast calcium sensor for fusion in chromaffin cells. Second, the main promoting effect of WT Doc2B expression is to increase the size of the RRP, which is an effect upstream of fusion. No consistent effect on the rate constant of release, or its Ca^2+^-sensitivity, was observed by the wildtype or mutated Doc2B protein (with the exception of the DN mutation, see below), see also ([@bib40]). This is in stark contrast to mutations reducing the Ca^2+^-affinity of syt-1 ([@bib45]), compromising syt-1:SNARE-binding ([@bib32]), deletion of complexin ([@bib10]), or interference with the C-terminal zippering of the SNARE-complex ([@bib48]; [@bib59]), which all compromise fusion time constants, reflecting the known function of the syt-1:SNARE:complexin supercomplex in fusion triggering. Third, the main effect of mutating the Ca^2+^ coordinating residues of Doc2B was to render overall vesicle priming Ca^2+^-independent ([Figures 4](#fig4){ref-type="fig"}--[5](#fig5){ref-type="fig"}). Fourth, we find that mutating the MID domain or removing ubMunc13-2 -- the major Munc13 isoform in chromaffin cells ([@bib29]) -- abolished the stimulating effect of Doc2B on priming ([Figure 1D](#fig1){ref-type="fig"}). Overall, therefore, we favor the idea that Doc2B acts through the recruitment of other factors, which cause vesicle priming.

Even as the indirect effects of Doc2B dominate in chromaffin cells, Doc2B appears to have a more direct effect on fusion in other systems, or after mutation. In neurons the DN mutation increases the mEPSC frequency ([@bib19]; [@bib15]), but it also increased synchronous release and RRP size ([@bib15]; [@bib61]), and when expressed in syt-1 KO neurons it supported a larger increase in asynchronous release than the WT protein ([@bib61]). When expressed in adrenal chromaffin cells the DN-mutant was the only tested mutant which decreased the time constant of fast burst fusion ([Figure 4K](#fig4){ref-type="fig"}), suggesting a function in accelerating fusion itself. These observations would be consistent with the idea that the DN mutation -- in addition to locating Doc2B at the membrane -- potentiates a direct function of Doc2B in fusing membranes. This function might dominate in neurons because the small synaptic vesicles are intrinsically more fusogenic due to their high curvature (or for other reasons), but only become noticeable in chromaffin cells in the context of the DN-mutant.

The negative effect that Doc2B exerts on sustained release in chromaffin cells ([Figure 1](#fig1){ref-type="fig"}) is not an artifact of a high expression level, because sustained release is augmented in the Doc2B KO compared to WT cells from littermates ([@bib40]), indicating that the endogenous expression level suffices for the effect. The effect can also be seen when stimulating by depolarization from a low resting \[Ca^2+^\] (\~100 nM) through augmentation of 'delayed release' between stimulations in Doc2B KO cells ([@bib40]). Overexpression of Doc2B or its mutants did not change staining for syb2, a vesicular marker ([Figure 2](#fig2){ref-type="fig"}). This is an important control, because overexpression of Doc2B increases spontaneous release in chemical synapses ([@bib19]). Increased spontaneous release might in principle lead to vesicle depletion and a secondary reduction in sustained release, although this is unlikely as the effect on spontaneous release is modest (a factor of \~2) and did not change RRP size in synapses ([@bib19]). Using electron microscopy, we previously ([@bib40]) reported a significant increase in the number of granules upon Doc2B expression. This increase was not reflected in a changed syb2 expression in this manuscript. Electron microscopy and immunostaning are very different methods for assessing vesicle abundance, and further experiments will be required to understand the reason for this apparent discrepancy. The phenotype of increased RRP and inhibited sustained was previously found after overexpression of open syntaxin-1 ([@bib26]), which together with our observation that Doc2B recruits syntaxin-1 from plasma membrane clusters ([@bib53]) suggest an explanation for the phenotype. However, the KE-mutation, which did not recruit syntaxin-1, still limited sustained release. The inhibitory function was partly relieved after deletion of the entire MID-domain. Inhibition dominated when Doc2B was expressed in Munc13-2 KO cells, but in these cells the fast and slow bursts of release were also reduced, along with the sustained component. This indicates that vesicle priming is fundamentally different in Munc13-2 KO cells. Priming in chromaffin and PC12 cells depends on Munc13 and CAPS proteins ([@bib26]; [@bib22]). Munc13-1 requires CAPS-1 to be able to increase secretion in chromaffin cells ([@bib26]). The major Munc13 variant in chromaffin cells is ubMunc13-2 ([@bib29]), but the specific interactions between ubMunc13-2 and CAPS-1/2 -- and between ubMunc13-2 and Doc2B -- remain essentially unexplored. Interestingly, expressing Munc13-1 in chromaffin cells yields a higher value of the ratio between burst/sustained, \~0.7 at 4 s post-flash, whereas ubMunc13-2 supported a relatively larger sustained component, yielding a ratio between burst/sustained of \~0.4 ([@bib29]). CAPS-proteins are required for the sustained release component in chromaffin cells ([@bib27]; [@bib26]) and traffic to the membrane on secretory vesicles ([@bib21]); therefore we can hypothesize that ubMunc13-2 displays more efficient coupling to CAPS activity than Munc13-1. It is an attractive possibility that Doc2B might target one Munc13 paralog (Munc13-1) selectively to the release machinery, thus accounting for a larger primed vesicle pool, while sustained release is limited by an additional function of Doc2B to block interactions with CAPS-proteins or the upstream Ca^2+^-sensor for priming (*priming 1*, [Figure 10](#fig10){ref-type="fig"}).

In conclusion, we show here that localization of Doc2B to the plasma membrane occludes the upstream Ca^2+^-dependent priming step ([@bib5]; [@bib57]; [@bib56]), and that Doc2B acts as a calcium sensor for vesicle priming into the RRP ([Figure 10C](#fig10){ref-type="fig"}). We further demonstrate that this function includes interactions with SNAREs and Munc13-2, and it further requires syt-1 to be present. Another, upstream, Ca^2+^-dependent priming factor is present in chromaffin cells, as vesicle priming remains Ca^2+^-dependent even in the Doc2B KO. Another function of Doc2B in adrenal chromaffin cells is to limit sustained release. This function also depends on the MID-domain, and we tentatively suggest that Doc2B might target some priming factors (Munc13, CAPS) selectively to the exocytotic cascade to shape overall release kinetics. Thus, the end result of Doc2A/B function will depend on the priming factors expressed in a particular cell and therefore will vary between systems. This might account for the different functions of Doc2B in beta cells, (increased biphasic insulin release \[[@bib43]\]), adrenal chromaffin cells (increase in RRP, but decrease in sustained release \[[@bib40]\]), and neurons (increase in spontaneous and/or asynchronous release \[[@bib19]; [@bib38]; [@bib62]\]).

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\      Designation                   Source or reference                        Identifiers             Additional information
  or resource                                                                                                                   
  ---------------------------- ----------------------------- ------------------------------------------ ----------------------- --------------------------------
  strain, strain background\   C57BL/6                                                                                          
  (M. musculus)                                                                                                                 

  strain, strain background\   CD1                                                                                              
  (M. musculus)                                                                                                                 

  genetic reagent\             Doc2a null allele             Sakaguchi G, Manabe T, Kobayashi K,\       PMID: 10594652          
  (*M. musculus*)                                            Orita S, Sasaki T, Naito A, Maeda M,\                              
                                                             Igarashi H, Katsuura G, Nishioka H,\                               
                                                             Mizoguchi A, Itohara S, Takahashi T,\                              
                                                             Takai Y. Doc2alpha is an activity-\                                
                                                             dependent modulator of excitatory\                                 
                                                             synaptic transmission.\                                            
                                                             Eur J Neurosci. 1999 Dec;11(12):4262--8.                           

  genetic reagent\             Doc2b null allele             Groffen AJ, Martens S, Díez Arazola R,\    PMID: 20150444          
  (*M. musculus*)                                            Cornelisse LN, Lozovaya N, de Jong AP,\                            
                                                             Goriounova NA, Habets RL, Takai Y,\                                
                                                             Borst JG, Brose N, McMahon HT,\                                    
                                                             Verhage M. Doc2b is a high-affinity\                               
                                                             Ca2+ sensor for spontaneous\                                       
                                                             neurotransmitter release. Science.\                                
                                                             2010 Mar 26;327 (5973):1614--8.                                    

  genetic reagent\             Synaptotagmin-7\              Maximov A, Lao Y, Li H, Chen X,\           PMID: 18308933          
  (*M. musculus*)              (syt7) null allele            Rizo J, Sørensen JB, Südhof TC.\                                   
                                                             Genetic analysis of synaptotagmin-7\                               
                                                             function in synaptic vesicle\                                      
                                                             exocytosis. Proc Natl Acad Sci U S A.\                             
                                                             2008 Mar 11;105(10):3986--3991.                                    

  genetic reagent\             Synaptotagmin-1\              Geppert M, Goda Y, Hammer RE,\             PMID: 7954835           
  (*M. musculus*)              (syt1) null allele            LI C, Rosahl TW, Stevens CF,\                                      
                                                             Südhof TC. 1994. Synaptotagmin I:\                                 
                                                             a major Ca2 + sensor for transmitter\                              
                                                             release at a central synapse.\                                     
                                                             Cell 79(4): 717--727.                                              

  genetic reagent\             Unc13b null allele            Varoqueaux F, Sigler A, Rhee J-S,\         PMID: 12070347          
  (*M. musculus*)                                            Brose N, Enk C, Reim K, Rosenmund C.\                              
                                                             Total arrest of spontaneous and evoked\                            
                                                             synaptic transmission but normal\                                  
                                                             synaptogenesis in the absence of\                                  
                                                             Munc13-medicated vesicle priming.\                                 
                                                             Proc Natl Acad Sci U S A. 2002.\                                   
                                                             Jun 25; 99(13):9037--9042.                                         

  transfected construct\       pSFV-Doc2b-WT-\               Friedrich R, Groffen AJ, Connell E,\       Genbank\                local reference: SG\#334
  (*R. norvegicus*)            IRES-EGFP                     van Weering JR, Gutman O, Henis YI,\       Accession:\             
                                                             Davletov B, Ashery U. DOC2B acts as a\     EU635444.1              
                                                             calcium switch and enhances\                                       
                                                             vesicle fusion. J Neurosci. 2008\                                  
                                                             Jul 2;28(27):6794--806.                                            

  transfected construct\       pSFV-Doc2b-DN-\               Friedrich R, Groffen AJ, Connell E,\       Genbank\                derived from EU635444.1\
  (*R. norvegicus*)            IRES-EGFP                     van Weering JR, Gutman O, Henis YI,\       Accession:\             with indicated mutations
                                                             Davletov B, Ashery U. DOC2B acts as a\     EU635445.1              
                                                             calcium switch and enhances\                                       
                                                             vesicle fusion. J Neurosci. 2008\                                  
                                                             Jul 2;28(27):6794--806.                                            

  transfected construct\       pSFV-Doc2b-6A-\               this paper                                                         derived from EU635444.1\
  (*R. norvegicus*)            IRES-EGFP                                                                                        with indicated\
                                                                                                                                mutations

  transfected construct\       pSFV-Doc2b-KE-\               this paper                                                         derived from EU635444.1\
  (*R. norvegicus*)            IRES-EGFP                                                                                        with indicated\
                                                                                                                                mutations

  transfected construct\       pSFV-Doc2b-TCT-\              this paper                                                         derived from EU635444.1\
  (*R. norvegicus*)            IRES-EGFP                                                                                        with indicated\
                                                                                                                                mutations

  transfected construct\       pSFV-Doc2b-MID\               this paper                                                         derived from EU635444.1\
  (*R. norvegicus*)            (14-41)-IRES-EGFP                                                                                with indicated\
                                                                                                                                mutations

  transfected construct\       pSFV-Doc2b-MID\               this paper                                                         derived from EU635444.1\
  (*R. norvegicus*)            (Scrambled)-\                                                                                    with indicated\
                               IRES-EGFP                                                                                        mutations

  transfected construct\       pLenti-\                      this paper                                                         derived from\
  (*R. norvegicus*)            Doc2bEGFP-WT                                                                                     EU635444.1; local\
                                                                                                                                reference: J274\#2

  transfected construct\       pLenti-\                      this paper                                                         local reference:\
  (*R. norvegicus*)            Doc2bEGFP-DN                                                                                     J274\#7

  transfected construct\       pLenti-\                      this paper                                                         local reference:\
  (*R. norvegicus*)            Doc2bEGFP-6A                                                                                     K102\#33

  transfected construct\       pSFV-EGFP-\                   this paper                                                         local reference: \#480
  (*R. norvegicus*)            Doc2B-DeltaMID                                                                                   

  transfected construct ()                                                                                                      

  transfected construct ()                                                                                                      

  transfected construct ()                                                                                                      

  biological sample ()                                                                                                          

  antibody                     anti-syntaxin                 Synaptic System                            SySy: 110011            dil. 1:1000;\
                                                                                                                                Overnight/room\
                                                                                                                                temperature

  antibody                     anti-GFP                      Abcam                                      Ab13970                 dil. 1:1000;\
                                                                                                                                Overnight/room\
                                                                                                                                temperature

  antibody                     secondary Goat\               Invitrogen                                 Invitrogen: A11029      dil. 1:1000;\
                               anti-mouse\                                                                                      Overnight/4 deg.
                               Alexa 488                                                                                        

  antibody                     secondary Goat\               Abcam                                      Ab150169                dil. 1:1000;\
                               anti-chicken\                                                                                    Overnight/4 deg.
                               Alexa 488                                                                                        

  antibody                     anti-\                        Synaptic System                            SySy: 105011            dil. 1:1000;\
                               synaptotagmin-1                                                                                  Overnight/4 deg.

  antibody                     anti-\                        Synaptic System                            SySy: 105173            dil. 1:500;\
                               synaptotagmin-7                                                                                  Overnight/4 deg.

  antibody                     anti-VCP                      Abcam                                      Ab11433                 dil. 1:2000;\
                                                                                                                                1h/room temperature

  antibody                     mouse mAb against\            Synaptic Systems GmbH                      cat\#104211             1:2500 diluted in\
                               Syb2, clone 69.1                                                                                 PBS+ 2% BSA,\
                                                                                                                                incubated 2 hr at RT

  antibody                     rabbit pAb\                   Groffen AJ, Brian EC, Dudok JJ,\           PMID: 15033971          1:133 diluted in\
                               against Doc2b                 Kampmeijer J, Toonen RF, Verhage M.\                               PBS+ 2% BSA,\
                                                             Ca(2+)-induced recruitment of the\                                 incubated 2 hr at\
                                                             secretory vesicle protein DOC2B to\                                RT (note: Doc2b and\
                                                             the target membrane. J Biol Chem.\                                 Syb2 stainings\
                                                             2004 May 28;279(22):23740--7.                                      were performed\
                                                                                                                                separately on\
                                                                                                                                different coverslips\
                                                                                                                                to rule out\
                                                                                                                                potential spectral\
                                                                                                                                overlap)/For\
                                                                                                                                western blotting: dil. 1:500;\
                                                                                                                                Overnight at 4 deg

  antibody                     Goat anti-rabbit HRP          Agilent                                    Dako-P0448              dil. 1:10000;\
                                                                                                                                1h30/room temperature

  antibody                     Goat anti-mouse HRP           Agilent                                    Dako-P0447              dil. 1:10000;\
                                                                                                                                1h30/room temperature

  antibody                     Goat-anti-Rabbit\             ThermoFisher Scientific                    cat\#A-11010            1:1000 diluted in PBS+ 2% BSA
                               Alexa546                                                                                         

  antibody                     Goat-anti-Mouse\              ThermoFisher Scientific                    cat\#10739374           1:1000 diluted in PBS+ 2% BSA
                               Alexa647                                                                                         

  antibody                                                                                                                      

  recombinant DNA reagent                                                                                                       

  sequence-based reagent                                                                                                        

  peptide, recombinant\                                                                                                         
  protein                                                                                                                       

  commercial assay or kit      BCA Protein\                  Pierce                                     Pierce: 23227           
                               assay kit                                                                                        

  commercial assay or kit                                                                                                       

  commercial assay or kit                                                                                                       

  chemical compound, drug      NaCl                          Sigma-aldrich                              Sigma-aldrich: S9888    

  chemical compound, drug      KCl                           Sigma-aldrich                              Sigma-aldrich: P5405    

  chemical compound, drug      NaH2PO4                       Sigma-aldrich                              Sigma-aldrich: S8282    

  chemical compound, drug      Glucose                       Sigma-aldrich                              Sigma-aldrich: G8270    

  chemical compound, drug      DMEM                          Gibco                                      Gibco: 31966047         

  chemical compound, drug      L-cysteine                    Sigma-aldrich                              Sigma-aldrich: C7352    

  chemical compound, drug      CaCl2                         Sigma-aldrich                              Sigma-aldrich: 499609   

  chemical compound, drug      EDTA                          Sigma-aldrich                              Sigma-aldrich: E5134    

  chemical compound, drug      papain                        Worthington Biochemical                    Worthington\            
                                                                                                        Biochemical:\           
                                                                                                        LS003126                

  chemical compound, drug      albumin                       Sigma-aldrich                              Sigma-aldrich: A3095    

  chemical compound, drug      trypsin-inhibitor             Sigma-aldrich                              Sigma-aldrich: T9253    

  chemical compound, drug      penicillin/\                  Invitrogen                                 Invitrogen: 15140122    
                               streptomycin                                                                                     

  chemical compound, drug      insulin-transferrin-\         Invitrogen                                 Invitrogen: 51500056    
                               selenium-X                                                                                       

  chemical compound, drug      fetal calf serum              Invitrogen                                 Invitrogen: 10500064    

  chemical compound, drug      MgCl2                         Sigma-aldrich                              Sigma-aldrich: 449172   

  chemical compound, drug      HEPES                         Sigma-aldrich                              Sigma-aldrich: H3375    

  chemical compound, drug      Nitrophenyl-\                 Synthesized at the Max-Planck-Institut\                            
                               EGTA (NPE)                    for biophycial chemistry, Göttingen.                               

  chemical compound, drug      Fura-4F                       Invitrogen                                 Invitrogen: F14174      

  chemical compound, drug      Furaptra                      Invitrogen                                 Invitrogen: M1290       

  chemical compound, drug      Mg-ATP                        Sigma-aldrich                              Sigma-aldrich: A9187    

  chemical compound, drug      GTP                           Sigma-aldrich                              Sigma-aldrich: G8877    

  chemical compound, drug      Vitamin C                     Sigma-aldrich                              Sigma-aldrich: A5960    

  chemical compound, drug      EGTA                          Sigma-aldrich                              Sigma-aldrich: E4378    

  chemical compound, drug      Paraformaldehyde              Sigma-aldrich                              Sigma-aldrich: P6148    

  chemical compound, drug      PIPES                         Sigma-aldrich                              Sigma-aldrich: 80635    

  chemical compound, drug      Triton X-100                  Sigma-aldrich                              Sigma-aldrich: T8787    

  chemical compound, drug      BSA                           Sigma-aldrich                              Sigma-aldrich: A4503    

  chemical compound, drug      Prolong Gold                  Invitrogen                                 Invitrogen: P36934      

  chemical compound, drug      Protease cocktail inhibitor   Invitrogen                                 Invitrogen: 87785       

  chemical compound, drug      RIPA buffer                   Invitrogen                                 Invitrogen: R0278       

  chemical compound, drug      ECL plus western\             Pierce                                     Pierce: 32132           
                               blotting substrate                                                                               

  chemical compound, drug                                                                                                       

  chemical compound, drug                                                                                                       

  chemical compound, drug                                                                                                       

  chemical compound, drug                                                                                                       

  software, algorithm          Igor                          wavemetrics                                                        

  software, algorithm          ImageJ                        NIH software                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

Chromaffin cell culture {#s4-1}
-----------------------

Doc2B knockout (KO) animals were generated by crossing heterozygous mice. Doc2A/B double knockout mice were kept homozygous knockout for both alleles. P0-P1 pups of either sex were sacrificed by decapitation, the adrenal glands dissected out, and chromaffin cells isolated and cultured according to previously published protocols ([@bib47]). Briefly, dissected adrenal glands were placed in filtered Locke's solution (154 mM NaCl, 5.6 mM KCl, 0.85 mM NaH~2~PO~4~, 2.15 mM Na~2~HPO~4~, and 10 mM glucose, pH 7.0), and cleaned for connective tissue using tweezers. The glands were digested in 0.3 mL of papain solution (solutions are defined below) at 37°C for 40 min followed by the addition of 0.3 mL of inactivating solution for 5--10 min. This solution was then replaced by 160 µL of enriched DMEM, and the glands triturated through a 200 µL pipette tip. 50 µL of the cell suspension were plated as a drop on glass coverslips in 6-well plates, and the cells were allowed to settle for 20--40 min before adding 2 mL of enriched DMEM. The cells were incubated at 37°C and 8% CO~2~ and used within 4 days. Papain solution: DMEM (Gibco) supplemented with 0.2 mg/mL L-cysteine, 1 mM CaCl~2~, 0.5 mM EDTA, and 20--25 U/mL papain (Worthington Biochemical) and equilibrated with 8% CO~2~. Inactivating solution: DMEM supplemented with 10% heat-inactivated fetal calf serum (Invitrogen), 2.5 mg/mL albumin, and 2.5 mg/mL trypsin inhibitor (Sigma-Aldrich). Enriched DMEM: DMEM supplemented with 4 µL/mL penicillin/streptomycin (Invitrogen) and 10 µL/mL insulin-transferrin-selenium-X (Invitrogen).

Expression constructs {#s4-2}
---------------------

For short-term re-expression experiments, full-length WT Doc2B, or Doc2B containing specific mutations, were cloned into a Semliki Forest Virus expression vector (pSFV1) containing an Internal Ribosomal Entry Site (IRES) followed by EGFP, to allow for the simultaneous, but independent, expression of both proteins. Fusion-constructs between Doc2B WT, DN and 6A mutants and EGFP (fused to the C-terminus of Doc2B) were cloned in a lentiviral vector. All constructs were verified by sequencing. The generation of lentiviral and SFV particles followed standard protocols.

Live imaging experiments {#s4-3}
------------------------

Mouse chromaffin cells from CD1 animals (P0) were isolated and plated as described above. After 24 hr, the cells were infected with lentiviral constructs expressing either Doc2b wild-type, the DN mutant or the 6A mutant and all fused C-terminally to the EGFP in order to follow their trafficking in live imaging. For Doc2b ΔMID, 48 hr after primary culture, the cells were infected for 6 hr with a Semliki Forest Virus containing doc2b ΔMID fused to EGFP. After 6 (Semliki Forest virus) or 72 hr (lentiviruses) of infection, confocal imaging of GFP fluorescence (single optical section around the equatorial plane) was performed on a Zeiss LSM780 (488 nm, Argon laser) scanning confocal microscope using a Zeiss Plan-Apochromat 63x/NA 1.4 DIC M27 oil immersion objective (Carl Zeiss,Germany). First acquisition (control) was performed in the presence of extracellular solution (in mM: 145 NaCl, 2.8 KCl, 2 CaCl~2~, 1 MgCl~2~, 10 HEPES and 11 glucose, pH 7.2 (osmolarity adjusted to \~305 mOsm)) and imaging was repeated every minute after the application of elevated K^+^ solution (In mM: 88 NaCl, 59 KCl, 2 CaCl~2~, 1 MgCl~2~, 10 HEPES and 11 glucose, pH 7.2 (osmolarity adjusted to \~305 mOsm)) for 5 min ('high K^+^\') and finally every minute after washing with extracellular solution ('wash') for 5 min.

Exocytosis measurements {#s4-4}
-----------------------

Combined capacitance measurements and amperometric recordings were performed as described previously ([@bib33]) on a Zeiss Axiovert 10 equipped with an EPC-9 amplifier (HEKA Elektronik) for patch-clamp capacitance measurements and an EPC-7 plus (HEKA Elektronik) for amperometry. The release of catecholamines was triggered by UV flash-photolysis (JML-C2, Rapp Optoelektronik) of a caged-calcium compound, nitrophenyl-EGTA, which was infused into the cell via the patch pipette, or by membrane depolarization.

Intracellular calcium concentrations were determined using a mixture of two fluorescent dyes with different Ca^2+^-affinities \[fura-4F and furaptra, Invitrogen; ([@bib56]; [@bib46])\] which, after calibration, allow calcium concentration measurements over a large dynamic range. For the ratiometric determination of the \[Ca^2+^\]~i~ the excitation light (monochromator IV, TILL Photonics, Gräfelfing, Germany) was alternated between 350 nm and 380 nm. The emitted fluorescence was detected with a photodiode and sampled using Pulse software (HEKA Elektronik, Lambrecht/Pfalz, Germany), which was also used for controlling the voltage in the pipette and performing capacitance measurements. The 350/380 fluorescence signal ratio was calibrated by infusion of cells with eight different solutions of known calcium concentrations. The standard intracellular solution contained (in mM): 100 Cs-glutamate, 8 NaCl, 4 CaCl~2~, 32 Cs-HEPES, 2 Mg-ATP, 0.3 GTP, 5 NPE, 0.4 fura-4F, 0.4 furaptra, and 1 Vitamin C (to prevent UV-induced damage to the fura dyes), pH 7.2 (osmolarity adjusted to \~295 mOsm). For depolarization experiments, Ca^2+^ and NPE were omitted, and EGTA (0.5 mM) was added to the intracellular solution to keep a low basal \[Ca^2+^\]~i~. The extracellular solution was composed of (in mM): 145 NaCl, 2.8 KCl, 2 CaCl~2~, 1 MgCl~2~, 10 HEPES and 11 glucose, pH 7.2 (osmolarity adjusted to \~305 mOsm).

Amperometric recordings were performed using carbon fiber electrodes with 5 µm in diameter (Thornel P-650/42; Cytec, NJ, USA), insulated using the polyethylene method ([@bib9]). Amperometry fibers were clamped to 700 mV, and currents were low-pass filtered with a 7-pole Bessel filter at 1 kHz using an EPC-7 plus (HEKA) and sampled at 11.5 kHz.

Kinetic analysis and priming propensities {#s4-5}
-----------------------------------------

Pool sizes and fusion rates were determined by fitting individual capacitance traces with a sum of three exponential functions, each of the form A(1-exp(-t/τ)), representing the fast burst (time constant, τ, 10--30 ms), the slow burst (time constant, τ, 70--300 ms) and the sustained component (time constant, τ, \>1 s), respectively, using procedures written in IGOR Pro software. Since the time constant of the sustained component often approached or exceeded the measurement time (5 s), only the mean linear rate of sustained release within 5 s was reported.

To understand the propensities for forward priming in the two sequential priming steps, *priming 1* and *priming 2* ([Figure 10](#fig10){ref-type="fig"}), we solved the two differential equations$$\frac{d\text{SRP}}{dt} = k_{1}\text{Depot\ +}k_{- 2}\text{RRP} - \left( {k_{- 1} + k_{2}} \right)\text{SRP}$$$$\frac{d\text{RRP}}{dt} = k_{2}\text{SRP} - k_{- 2}\text{RRP}$$

under steady-state assumptions (i.e. the left-hand side were put equal to zero), which yields$$\frac{k_{1}\text{Depot}}{k_{- 1}} = \text{SRP}_{0}$$$$\frac{k_{2}}{k_{- 2}} = \frac{\text{RRP}_{0}}{\text{SRP}_{0}}$$

where RRP~0~ and SRP~0~ are the steady-state values of the two pool sizes. We estimated the RRP~0~ and SRP~0~ from the response to Ca^2+^-uncaging; the underlying assumptions are that pools are at equilibrium, that the product of *k~1~* and the Depot size is a constant and that there was no ongoing fusion before stimulation.

Immunocytochemistry {#s4-6}
-------------------

For immunostaining against Doc2B and VAMP2, chromaffin cells were prepared from Doc2A/B double-knockout pups at postnatal day P1. Doc2A/B double knockouts were used for these experiments due to availability, but note that Doc2A is not expressed in adrenal chromaffin cells ([@bib14]; [@bib40]). Eight h post infection with Semliki Infective Particles encoding Doc2b-IRES-EGFP, Doc2B mutants --IRES-EGFP or IRES-EGFP alone as a control, the cells were fixed by adding an equal volume of 4% PFA in PBS to the existing culture medium, yielding a final concentration of 2% PFA. The cells were washed in PBS, permeabilized for 5 min at RT with 0.1% Triton-X100, washed again with PBS, and incubated in PBS containing rabbit polyclonal antiserum 13.2 against Doc2B ([@bib17]) (diluted 1:133) or monoclonal mouse anti-VAMP2 (Synaptic Systems, clone 69.1, diluted 1:2000) for 2 hr at room temperature. The cells were washed 3x for 10 min with PBS and incubated with secondary goat-anti-mouse-A647 and goat-anti-rabbit-A546 (Molecular probes, both diluted 1:1000) for 2.5 hr at RT. The cells were washed 3x for 30 min and mounted in Mowiol. Confocal imaging of A647, A546 and GFP fluorescence was performed on a Zeiss LSM510 microscope using a 63x oil immersion objective.

For immunostaining against syntaxin-1, cells were first prefixed for 5 min in isosmotic fixative containing 0.9% PFA in 0.05 M 1,4-piperazinediethanesulfonic acid (PIPES)/NaOH (pH 7.4, 310 mOsm) 2.8 mM KCl and 1 mM MgCl. This was followed by 8 min of incubation in 3.7% PFA in 0.05 M PIPES/NaOH (pH 7.4). Afterward, the cells were washed three times with PBS (pH 7.4) and permeabilized for 10 min in PBS containing 0.1% Triton X-100 (Sigma-Aldrich), followed by 30 min of blocking in PBS containing 3% BSA. The blocking solution was used for diluting antibodies. The chromaffin cells were incubated overnight with a cocktail of anti-syntaxin 1 and anti-GFP antibodies (1:1000; anti-syntaxin-1, cat. no. 110011; Synaptic Systems and chicken anti-EGFP, cat no. ab13970; Abcam) at room temperature, washed three times with PBS, and incubated with secondary goat anti-mouse Alexa 546 and goat anti-chicken Alexa 488 antibodies (1:1000: Life Technologies) overnight at 4°C. After extensive washings with PBS, cells were rinsed with water and mounted on microscopic slides with Prolong Gold (Invitrogen). For this series of experiments, confocal images were acquired with a HCX PL APO CS lens (NA 1.4; Leica Microsystems A/S) with frame size of 512 × 512 and a zoom factor 10 on a LEICA SP5-X Confocal microscope (Leica Microsystems). Images were corrected for background fluorescence by subtracting an average intensity value of an area not containing any cells. Fluorescence levels of the plasma membrane were quantified by measuring the integrated intensity of a ROI1, defined as the outer edge of the plasma membrane, and subtracting the integrated density of a ROI 2, defined as the inner edge of the membrane. The increase in syntaxin-1 staining by Doc2B expression is more modest using this isosmotic fixation method than with standard PFA-fixation ([@bib53]).

Electrophoresis and immunoblotting {#s4-7}
----------------------------------

Adrenal glands were collected from P0-2 Syt-7 oe E18 Syt-1 mice and lysed in RIPA buffer (Invitrogen) supplemented with Protease Inhibitor Cocktail (Invitrogen). The protein concentrations were determined by use of a BCA Protein Assay Kit (Pierce; cat.no.23227). 20 μg (from adrenal glands samples) of protein were resolved by SDS-PAGE, transferred to nitrocellulose and blotted using anti Doc2B (rabbit pAb 13.2 from Matthijs Verhage laboratory, dil. 1:500), Synaptotagmin-1 (mouse, Synaptic System, Cat. no. SYSY 105011, dil. 1:1000), Synaptotagmin-7 (rabbit, Synaptic System, Cat. no. SYSY 105173, dil. 1:500), or VCP (as loading control, mouse, Abcam, Cat. no. ab11433, dil. 1:2000) antibodies. The blots were developed by chemiluminescence using the ECL plus western blotting substrate system (Pierce). Immunoreactive bands were detected using the FluorChemE image acquisition system (ProteinSimple) and quantified with ImageJ 1.47q (National Institutes of Health).

Statistics {#s4-8}
----------

Data are presented as mean ±SEM, with *n* indicating the number of cells, and statistical comparisons were made in Graphpad Prism. For every mutant or overexpression condition, we performed control experiments (non-expressing or Doc2B WT expressing) and overexpression/mutant experiments in parallel using cells isolated from the same animals. When testing two conditions, we used a F-test to test for differences in variance. In case the F-test was significant, we performed a Mann-Whitney test, otherwise we used an unpaired two-tailed Student's t-test. In case of three conditions measured in parallel, we tested deviations from homoscedasticity using a Bartlett's test; if the test was significant, we used a Kruskal-Wallis test and Dunn's test for multiple comparison, otherwise we used an ANOVA and Tukey's post-hoc test. For live imaging experiments ([Figure 3C](#fig3){ref-type="fig"}), we performed a one-sample t-test comparing the change in fluorescence ratio upon stimulation to zero.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Doc2B acts as a calcium sensor for vesicle priming requiring synaptotagmin-1, Munc13-2 and SNAREs\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Randy Schekman as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission

Summary:

The manuscript by Houy et al. addresses the role of the Ca^2+^-binding protein Doc2B in secretion from chromaffin cells. By this, the manuscript lines up as a highly significant study in a row of important contributions over the last years studying the function of this protein in secretion from either neurons or neuroendocrine cells. For example, previous work has implicated Doc2B as a Ca^2+^-sensor for spontaneous (Groffen et al., 2010) and asynchronous neurotransmitter release (Yao et al., 2011). In addition, Do2B binds to Munc13-proteins and the SNAREs. Most experiments assess exocytosis by capacitance measurements and amperometry. Exocytosis is stimulated in these experiments by uncaging intracellular Ca^2+^ in the patch clamp whole cell configuration. The experiments are well designed, and the overall quality of the data is excellent.

The results show that Doc2B increases the exocytotic burst and thus the readily releasable pool but it also inhibits the sustained component, which is generally thought to reflect the recruitment followed by the release of unprimed vesicles. They conclude that the action of Doc2B involves Ca^2+^ binding and associated translocation to the plasma membrane and that mutations that do not bind Ca^2+^ and are permanently associated with the plasma membrane are constitutively active, independent of Ca^2+^ binding. In contrast, no changes in Ca^2+^-dependent priming could be detected in Doc2B null mutants ([Figures 2](#fig2){ref-type="fig"} and [4](#fig4){ref-type="fig"}, see also Pinheiro et al., 2013). The authors interpret these observations with the mutant proteins as evidence for Doc2B being a Ca^2+^-sensor for vesicle priming in chromaffin cells. By studying the effect of Doc2B expression in sytI KO and ub-Munc13-2 KO cells and by using specific mutant proteins (Doc2B KE mutant, K237E/K319E) they find that Doc2B action on priming relies on the presence of sytI, Munc13-2 and SNARE binding activity.

Essential revisions:

Reviewer 1:

While the manuscript contains very interesting data leading to novel conclusions some data are less clear and/or not clearly presented, which need to be addressed. Also, the Discussion section is rather confusing. The discussion should specifically address points 2, 4, and 9, listed below.

1\) In [Figure 1](#fig1){ref-type="fig"} an important control needs to be included, the overexpression of Doc2B in WT chromaffin cells that are not devoid of endogenous Doc2B background. This is important for assessment of the data in the Syt-1, Syt-7 and Munc13-2 KO cells, which presumably do express WT level Doc2B.

2\) [Figure 1](#fig1){ref-type="fig"} legend states overexpression. How do Doc2B expression levels in Doc2B KO cells compare quantitatively with Doc2B levels in WT chromaffin cells? The authors do not convincingly address the possibility that Doc2B abundance may be responsible for inhibition of the sustained phase and the reported effects seen in Syt-1 KO and Munc13-2 KO cells ([Figure 1B, D](#fig1){ref-type="fig"}). Syt-1 KO and Munc13-2 KO cells contain endogenous proteins and the overexpression of Doc2B WT may have introduced significantly more protein above background (this is unknown because this data is not included but pSFV is known to induce very high overexpression levels). In case of higher Doc2B protein expression in Syt1 KO+Doc2B WT versus Syt1 KO, there is a possibility that this difference may explain the observed decrease. The same could be said for the Munc13-2 KO experiment ([Figure 1D](#fig1){ref-type="fig"}).

3\) Subsection "Doc2B requires synaptotagmin-1 and Munc13-2 to stimulate priming", Figure 1Bii: The authors state that in absence of Syt-1, Doc2B has no effect on slow burst. However, the slow burst in syt1 KO is almost 50% larger than that in syt1 KO + Doc2B WT although the error bars are too large to achieve apparently p\<0.05 significance. Is this due to the smaller sample size? In Figure 1Ai, similar amount of difference between Doc2B KO and Doc2B KO+Doc2B WT is statistically significant, and the sample size is also larger than that in Figure 1Bii. As it stands, it remains unclear whether Doc2B has no effect on slow burst.

4\) In the Discussion section and elsewhere in the manuscript: The increase in burst amplitude in the presence of Doc2B is interpreted as promotion of a step towards priming upstream of fusion. It is not obvious why this could not as well be a consequence of Doc2B inhibiting release, which could also lead to a larger RRP and could at the same time explain the reduction of the sustained phase. While the data may contain evidence for rejecting such an alternative hypothesis it should at least be explicitly discussed in the Discussion section.

5\. The authors state that chromaffin cells do not express Doc2A (Subsection "Doc2B requires synaptotagmin-1 and Munc13-2 to stimulate priming"). However, [Figure 2](#fig2){ref-type="fig"}. Shows imaging data from Doc2A/B double knockout cells. How were these cells generated and why (not found in Materials and methods section)? All the other data are apparently from Doc2B single knockouts. Is there endogenous Doc2A in mouse chromaffin cells and if so how does that impact the conclusions?

6\) [Figure 2B](#fig2){ref-type="fig"} needs the quantification of CONTROL. As it stands, given the apparent Doc2B labeling in DKO cells, [Figure 2](#fig2){ref-type="fig"} is inconclusive. The intensity values in [Figure 2B](#fig2){ref-type="fig"} include the non-Doc2B-specific fluorescence in Control, which one would need to subtract to assess expression levels of the different constructs. Expression levels of different constructs may actually vary dramatically if that background subtraction is done. Also, for comparison staining intensity of unmodified WT cells would be important to quantify to determine the overexpression factors. This relates to point 2 above.

7\) In [Figure 3N](#fig3){ref-type="fig"} expression of Doc2B-EGFP appears to be much higher than that of Doc2B DN-EGFP, could this affect protein localization? In contrast [Figure 2](#fig2){ref-type="fig"} indicates that expression of the DN mutant is similar or higher than WT.

8\) What are the Doc2B expression levels for the different KO cells as used in [Figure 1](#fig1){ref-type="fig"} -- are they similar in WT, syt-1, syt-7, Munc13-2 knockout cells?

9\) [Figure 4A,G](#fig4){ref-type="fig"} indicates that the Ca^2+^-dependent priming as indicated by relative burst amplitude change is even higher in Doc2B KO than in Doc2B overexpressing cells. How does this fit with the author\'s conclusion that Doc2B is the Ca^2+^ sensor for priming?

10\) In the long pulse stimulations of [Figure 5](#fig5){ref-type="fig"} there seems to be no obvious exhaustion and it is not clear why the cumulative Cm increase is equated to RRP. Are the ratios of Cm responses informative for quantification of pool size? Is there more refilling between pulses than in experiments with WT chromaffin cells? Could the negative control data be included?

11\) In [Figure 6](#fig6){ref-type="fig"}: How do we know the increased labeling is due to syntaxin availability and not due to direct labeling of Doc2B? Has the labeling experiment been performed in Stx-1 KO cells +/- Doc2B? The negative control data (Doc2B KO) should be included in D-H.

12\) In [Figure 8C](#fig8){ref-type="fig"} it is not clear what the effect of Doc2B ∆MID is (if any) -- the control (Doc2B KO) needs to be included for this data set.

Reviewer 2:

1\) My major concerns deals with the central conclusion of the manuscript implicating now Doc2B as a Ca^2+^-sensor for vesicle priming, a notion that is largely based on the observation that the DN mutant and the 6A mutant abolishes any Ca^2+^-dependency of the vesicle priming reaction ([Figure 3M](#fig3){ref-type="fig"} and [4M](#fig4){ref-type="fig"}). In general, this notion seems to be difficult to reconcile with previous conclusions by the authors implicating Doc2B as the Ca^2+^-sensor for spontaneous release in neurons spontaneous (Groffen et al., 2010) and others suggesting a function as a Ca^2+^-sensor for asynchronous transmitter release (Yao et al., 2011). Furthermore, the authors themselves have previously reported, otherwise (Pinheiro et al., 2013). By analyzing the exocytotic burst size over a wide range of preflash \[Ca^2+^\]I in wild type and Doc2B-KO cells, they could show that Doc2B has no obligatory role in driving the Ca^2+^-dependent priming reaction upstream of the slowly releasable pool. Also in the present manuscript the authors find the Ca^2+^-dependency of the priming reaction of chromaffin vesicles to be unperturbed in cells of Doc2B null mutants when compared with controls (see [Figure 3](#fig3){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}).

While the lack of effect with null mutant cells could be readily explained by functionally redundant isoforms, it is similarly possible that mutating Doc2B endows special properties that allow the protein to bypass the classical priming reaction. Previous studies using similar mutations have indeed suggested that mutations in the C2A region of Doc2B (intended to disrupt Ca^2+^-binding) resulted in an anomalous increase in constitutive membrane binding and thereby provide Doc2B with novel functional properties (Gaffaney et al., 2014). Thus, I\'m not convinced that these experiments with the mutant proteins (DN and 6A mutation) provide clear evidence that Doc2B acts as a Ca^2+^-sensor in vesicle priming. The apparent gain-of-function mutation may rather result from anomalous membrane binding activity. The latter is only displayed as exemplary results ([Figure 3N](#fig3){ref-type="fig"} and [Figure 4N](#fig4){ref-type="fig"}) and should be presented in a quantitative fashion. I also recommend to study the dependence of the burst size on preflash \[Ca^2+^\]i over a wider range of Ca^2+^- concentrations, as presented for example by Pinheiro et al., 2013 ([Figure 5C](#fig5){ref-type="fig"}), to provide a better understanding of the underlying mechanisms.

2\) Previously, the authors have shown that overexpressing Doc2b increased significantly the total number of vesicles per cell as well as the number of membrane-proximal vesicles (Pinheiro et al., 2013). This raises the question, to what extent apparent changes in priming with the DN and 6A mutation are accompanied by alterations in vesicle number and whether a similar phenotype can be observed with the mutant proteins. In this context, I do not understand the authors\' statement in subsection "Doc2B supports vesicle priming as a calcium sensor": \"The DN-mutant was expressed at similar levels as WT Doc2B, and VAMP2/synaptobrevin-2 staining also showed similar levels, consistent with an unperturbed granule density in the presence of Doc2B expression ([Figure 2B-C](#fig2){ref-type="fig"}).\" The authors should clarify this point.

3\) The most prominent phenotype in Doc2B KO seems to be the enhanced sustained release under prolonged elevation of \[Ca^2+^\]i. This action of Doc2B is dependent on its MID-domain ([Figure 8C](#fig8){ref-type="fig"}) but curiously not on its interaction with Munc 13-2 ([Figure 1D](#fig1){ref-type="fig"}). The authors hypothesized a secondary function of Doc2B that blocks interactions with CAPS-proteins leading to inhibition of sustained release. While intriguing, the authors provide no evidence for an interaction between Doc2B MID domain and CAPS-protein. Furthermore, functional studies of Doc2B action in CAPS KO are required to draw such conclusions, in absence of which the readers are left with rather incomplete understanding of the inhibitory action of Doc2B. Thus, it might be helpful to study the Doc2B-CAPS interactions to better clarify the mechanism of inhibitory Doc2B function in chromaffin cells.

4\) It remains unclear why specifically the RRP but not the IRP is altered with Doc2B DN mutant expression.

10.7554/eLife.27000.018

Author response

> Essential revisions:
>
> Reviewer 1:
>
> 1\) In [Figure 1](#fig1){ref-type="fig"} an important control needs to be included, the overexpression of Doc2B in WT chromaffin cells that are not devoid of endogenous Doc2B background. This is important for assessment of the data in the Syt-1, Syt-7 and Munc13-2 KO cells, which presumably do express WT level Doc2B.

The reviewer is right; overexpression in WT chromaffin cells is an important control. We have now performed this control and included it as [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. Due to the already very large [Figure 1](#fig1){ref-type="fig"}, we could not include it there. The data shows an increase in primed vesicle pools (and a decrease in the sustained component). In contrast to Doc2B over-expression in KO cells, the SRP was also increased by Doc2B expression in WT cells (CD1 mice). We point out and discuss this finding in the revised manuscript.

> 2\) [Figure 1](#fig1){ref-type="fig"} legend states overexpression. How do Doc2B expression levels in Doc2B KO cells compare quantitatively with Doc2B levels in WT chromaffin cells? The authors do not convincingly address the possibility that Doc2B abundance may be responsible for inhibition of the sustained phase and the reported effects seen in Syt-1 KO and Munc13-2 KO cells ([Figure 1B, D](#fig1){ref-type="fig"}). Syt-1 KO and Munc13-2 KO cells contain endogenous proteins and the overexpression of Doc2B WT may have introduced significantly more protein above background (this is unknown because this data is not included but pSFV is known to induce very high overexpression levels). In case of higher Doc2B protein expression in Syt1 KO+Doc2B WT versus Syt1 KO, there is a possibility that this difference may explain the observed decrease. The same could be said for the Munc13-2 KO experiment ([Figure 1D](#fig1){ref-type="fig"}).

The presentation of immunostainings in [Figure 2](#fig2){ref-type="fig"} was not clear, because the background level was not included explicitly, so the overexpression level was not clear. This has now been corrected by performing new stainings (see also below). As for the rest of the question, we realized that we did not define the rationale for the experiment: it was the purpose of our experiment to induce significantly more protein above background, to push the system to show a clear effect of Doc2B. The question is whether that level of overexpression leads to artefacts. This is not the case, because the overexpression in WT or Doc2B KO cells results in an increase of primed vesicle pools, and a decrease in sustained release. This is entirely consistent with the decrease in primed vesicle pools (seen best during repetitive depolarization stimulations) and the increase in sustained release identified in the Doc2B knockout when compared to WT littermates (Pinheiro et al., 2013). We added this rationale to the Results section.

> 3\) Subsection "Doc2B requires synaptotagmin-1 and Munc13-2 to stimulate priming", Figure 1Bii: The authors state that in absence of Syt-1, Doc2B has no effect on slow burst. However, the slow burst in syt1 KO is almost 50% larger than that in syt1 KO + Doc2B WT although the error bars are too large to achieve apparently p\<0.05 significance. Is this due to the smaller sample size? In Figure1Ai, similar amount of difference between Doc2B KO and Doc2B KO+Doc2B WT is statistically significant, and the sample size is also larger than that in Figure 1Bii. As it stands, it remains unclear whether Doc2B has no effect on slow burst.

As mentioned in the figure legend, we measured 18 syt-1 KO cells and 20 syt-1 KO cells overexpressing Doc2B, which are reasonable numbers. However, the slow burst is the hardest phase to quantify, because it is sandwiched between the fast burst and the sustained component. Therefore, it is always a risk that the reduction in the sustained component (as seen with Doc2B overexpression) could leak into the slow burst and appear as a reduction there. Therefore, we feel we cannot make strong statements about the slow burst if the other phases are changed as well. We have now pointed this out in the text.

> 4\) In the Discussion section and elsewhere in the manuscript: The increase in burst amplitude in the presence of Doc2B is interpreted as promotion of a step towards priming upstream of fusion. It is not obvious why this could not as well be a consequence of Doc2B inhibiting release, which could also lead to a larger RRP and could at the same time explain the reduction of the sustained phase. While the data may contain evidence for rejecting such an alternative hypothesis it should at least be explicitly discussed in the Discussion section.

This is a good point, and we now discuss it in the Discussion section. In our previous work (Pinheiro et al., 2013), we could not make this distinction, but now we can, because we here identify several mutations, where the increase in RRP is absent, but the decrease in sustained release is still detected. So, we have separated those two functions by mutation (see first paragraph of Discussion section).

> 5\. The authors state that chromaffin cells do not express Doc2A (Subsection "Doc2B requires synaptotagmin-1 and Munc13-2 to stimulate priming"). However, [Figure 2](#fig2){ref-type="fig"}. Shows imaging data from Doc2A/B double knockout cells. How were these cells generated and why (not found in Materials and methods section)? All the other data are apparently from Doc2B single knockouts. Is there endogenous Doc2A in mouse chromaffin cells and if so how does that impact the conclusions?

Doc2A is not expressed in chromaffin cells (Friedrich et al., 2008; Pinheiro et al., 2013), which we mentioned in the manuscript. The staining was done in Doc2A/B double-KO cells, because the Doc2B single KO mouse line was not available in the laboratory when these experiments were performed. This should not have any impact on results, because Doc2A is not expressed. We have now added this explanation and the description of this mouse line to the Materials and methods section.

> 6\) [Figure 2B](#fig2){ref-type="fig"} needs the quantification of CONTROL. As it stands, given the apparent Doc2B labeling in DKO cells, [Figure 2](#fig2){ref-type="fig"} is inconclusive. The intensity values in [Figure 2B](#fig2){ref-type="fig"} include the non-Doc2B-specific fluorescence in Control, which one would need to subtract to assess expression levels of the different constructs. Expression levels of different constructs may actually vary dramatically if that background subtraction is done. Also, for comparison staining intensity of unmodified WT cells would be important to quantify to determine the overexpression factors. This relates to point 2 above.

The reviewer is correct. We have now replaced [Figure 2](#fig2){ref-type="fig"} with new data, which includes stainings of controls. Staining of WT cells (cells from Doc2B WT mice) in parallel show that our antibody cannot detect endogenous protein in immunocytochemistry and produces some non-specific staining, probably due the presence of other epitopes in DKO cells. Nevertheless, expression of Doc2B in mouse adrenal chromaffin cells has been clearly shown by in situ hybridisation (Friedrich et al., 2006 -- supplementary materials), and confirmed by analysis of the knockout cells, incl. the ability to rescue the phenotype with Doc2B expression (Pinheiro et al., 2013). Thus, the fact that the antibody cannot detect the endogenous protein is most likely an antibody sensitivity problem. This does not affect its ability to detect overexpressed protein, as it is present at higher levels.

> 7\) In [Figure 3N](#fig3){ref-type="fig"} expression of Doc2B-EGFP appears to be much higher than that of Doc2B DN-EGFP, could this affect protein localization? In contrast [Figure 2](#fig2){ref-type="fig"} indicates that expression of the DN mutant is similar or higher than WT.

We tested this possibility, but observed that the relative expression levels of the Doc2B DN and WT protein cannot be assessed by comparing their EGFP-fluorescence in live cells, because the two constructs do not have the same localization. In our Doc2B WT construct, when stimulating with high-K (so that the protein goes to the membrane), the total fluorescence is decreased -- this is reversible. This is probably due to self-quenching of EGFP when accumulating at the membrane, or recruitment to parts of the plasma membrane outside of the confocal slice. At the suggestion of reviewer \#2 we have now quantified live cell imaging experiments in a number of cells and include the quantification in a separate figure (new [Figure 3](#fig3){ref-type="fig"}). Since absolute intensities are not informative, quantifications are done on ratios (total fluorescence / fluorescence inside the cell). In addition, please note that the fusion constructs are not used for staining or electrophysiological experiments (for those experiments bicistronic constructs were used), therefore they cannot be directly compared to [Figure 2](#fig2){ref-type="fig"}.

> 8\) What are the Doc2B expression levels for the different KO cells as used in [Figure 1](#fig1){ref-type="fig"} -- are they similar in WT, syt-1, syt-7, Munc13-2 knockout cells?

We have performed Western Blot against Doc2B of Syt-1 KO and Syt-7 KO cells and included it in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}. The endogenous protein is hard to detect with the antibody, but no overt changes were noted. Our Munc13-2 KO mouse colony is currently not running, and we have not obtained any glands. Please note -- this is a point related to the point 2 above -- that no conclusion in our manuscript requires the Doc2B expression levels to be exactly the same in the KOs. The point of our experiment in [Figure 1](#fig1){ref-type="fig"} was to use overexpression to push the effect of Doc2B to the maximum, and test which of the other secretory proteins it depends on. We have added this rationale in the Results section.

> 9\) [Figure 4A,G](#fig4){ref-type="fig"} indicates that the Ca^2+^-dependent priming as indicated by relative burst amplitude change is even higher in Doc2B KO than in Doc2B overexpressing cells. How does this fit with the author\'s conclusion that Doc2B is the Ca^2+^ sensor for priming?

This is already discussed in the Discussion section: we show here that Doc2B is a Ca^2+^-sensor for priming, however there must be an overlapping or redundant pathway in chromaffin cells, since priming is still present in the KOs. We do not think this is very surprising. Munc13-2 has several Ca^2+^-binding sites and can probably be activated without Doc2B.

> 10\) In the long pulse stimulations of [Figure 5](#fig5){ref-type="fig"} there seems to be no obvious exhaustion and it is not clear why the cumulative Cm increase is equated to RRP. Are the ratios of Cm responses informative for quantification of pool size? Is there more refilling between pulses than in experiments with WT chromaffin cells? Could the negative control data be included?

The release until the end was found to be similar to the RRP in flash experiments, therefore we call it "RRP", but we discuss that it might not be exactly the same pool as the RRP found in flash data. We don't find the ratios very informative, since the depression is very small (or absent) in many cells and using ratios would therefore lead us to leave out many cells, making the analysis unrepresentative. There are no 'negative control data' here (or we don't understand what the reviewer means): as we describe, expression of Doc2B WT, or Doc2B DN led to strong inhibition of Calcium-currents; therefore, a comparison to uninfected cells is not meaningful.

> 11\) In [Figure 6](#fig6){ref-type="fig"}: How do we know the increased labeling is due to syntaxin availability and not due to direct labeling of Doc2B? Has the labeling experiment been performed in Stx-1 KO cells +/- Doc2B? The negative control data (Doc2B KO) should be included in D-H.

The antibody used is specific for syntaxin-1, as we have shown in another paper using BoNT/C expressing cells (Toft-Bertelsen et al., 2016). We now point this out in the manuscript. In that paper, we also showed that staining is increased within minutes when dispersing syntaxin-clusters directly using cholesterol extraction. In the present manuscript we show that syntaxin-1 staining is not increased when we mutate Doc2B to not bind to SNAREs (KE-mutant), which is another confirmation of the specificity of the effect (and the antibody). We do not have access to syntaxin-1 KO mice. We have included quantification of the KO condition in panels D-H.

> 12\) In [Figure 8C](#fig8){ref-type="fig"} it is not clear what the effect of Doc2B ∆MID is (if any) -- the control (Doc2B KO) needs to be included for this data set.

We have now included the Doc2B KO condition and discussed the effect of ∆MID clearer in the revised manuscript.

> Reviewer 2:
>
> 1\) My major concerns deals with the central conclusion of the manuscript implicating now Doc2B as a Ca^2+^-sensor for vesicle priming, a notion that is largely based on the observation that the DN mutant and the 6A mutant abolishes any Ca^2+^-dependency of the vesicle priming reaction ([Figure 3M](#fig3){ref-type="fig"} and [4M](#fig4){ref-type="fig"}). In general, this notion seems to be difficult to reconcile with previous conclusions by the authors implicating Doc2B as the Ca^2+^-sensor for spontaneous release in neurons spontaneous (Groffen et al., 2010) and others suggesting a function as a Ca^2+^-sensor for asynchronous transmitter release (Yao et al., 2011). Furthermore, the authors themselves have previously reported, otherwise (Pinheiro et al., 2013). By analyzing the exocytotic burst size over a wide range of preflash \[Ca^2+^\]I in wild type and Doc2B-KO cells, they could show that Doc2B has no obligatory role in driving the Ca^2+^-dependent priming reaction upstream of the slowly releasable pool. Also in the present manuscript the authors find the Ca^2+^-dependency of the priming reaction of chromaffin vesicles to be unperturbed in cells of Doc2B null mutants when compared with controls (see [Figure 3](#fig3){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}).
>
> While the lack of effect with null mutant cells could be readily explained by functionally redundant isoforms, it is similarly possible that mutating Doc2B endows special properties that allow the protein to bypass the classical priming reaction. Previous studies using similar mutations have indeed suggested that mutations in the C2A region of Doc2B (intended to disrupt Ca^2+^-binding) resulted in an anomalous increase in constitutive membrane binding and thereby provide Doc2B with novel functional properties (Gaffaney et al., 2014). Thus, I\'m not convinced that these experiments with the mutant proteins (DN and 6A mutation) provide clear evidence that Doc2B acts as a Ca^2+^-sensor in vesicle priming. The apparent gain-of-function mutation may rather result from anomalous membrane binding activity. The latter is only displayed as exemplary results ([Figure 3N](#fig3){ref-type="fig"} and [Figure 4N](#fig4){ref-type="fig"}) and should be presented in a quantitative fashion. I also recommend to study the dependence of the burst size on preflash \[Ca^2+^\]i over a wider range of Ca^2+^- concentrations, as presented for example by Pinheiro et al., 2013 ([Figure 5C](#fig5){ref-type="fig"}), to provide a better understanding of the underlying mechanisms.

We have now performed new experiments and included a quantification of the membrane binding activity of Doc2B WT, DN, 6A, and ΔMID in a new figure ([Figure 3](#fig3){ref-type="fig"}). This shows -- as we had previously described qualitatively -- that WT and ΔMID cycle on and off the plasma membrane upon treatment with High-K^+^ solution. Also the DN cycles to a minor degree (as we had mentioned also before), but it also displays a much higher membrane localization at rest than the WT; thus it is only a minor fraction of the DN mutant that cycles, since most resides at the membrane. The 6A-mutation does not cycle on and off the membrane, but remains at the plasma membrane. The reviewer raises the question whether the DN mutation has 'anomalous increase in constitutive membrane binding and thereby provides Doc2B with novel functional properties'. The decisive experiments that we performed here was to study the effect of expressing Doc2B WT and DN when stimulated from a low and a high basal-\[Ca^2+^\]. The striking result is that the DN is a gain-of-function mutant when studied from a low basal-\[Ca^2+^\], but -- when studied from a high basal \[Ca^2+^\] -- [it is indistinguishable from the WT]{.ul}. This latter fact indicates that the DN is not special or anomalous, except that it is already abundant at the membrane at very low \[Ca^2+^\]. The WT protein would not be at the membrane at low basal-\[Ca^2+^\], and thus the gain-of-function of the DN-mutant is entirely understandable from the trafficking behavior. The only exception is the fusion time constant of the RRP, which is significantly faster for the DN-mutant when studied from high basal-\[Ca^2+^\] (we commented on this also in the first version of the manuscript). In addition, we see basically the same behavior by another mutant -- the 6A-mutant -- which is unable to bind to Ca^2+^ at all, but which is also constitutively at the membrane. Also, this mutation is gain-of-function when studied from low basal-\[Ca^2+^\], although it is slightly inferior to the WT at high basal \[Ca^2+^\]. This permanent membrane localization of the 6A-mutation sheds new light on this mutation, which was previously used to argue that Doc2B might have Ca^2+^-independent effect (Pang et al., 2011); now we see that also this mutation bypasses Ca^2+^-binding by being permanently at the plasma membrane. We have not been able to extend the range of preflash \[Ca^2+^\] that we study, because of the huge amount of work that would be involved, in combination with the modest yield of cells from a single Doc2B embryo. As far as we can see, the current data provide very strong evidence for our conclusion that Ca^2+^-binding to Doc2B drives it to the membrane, which leads to membrane priming.

Our data here are consistent with our previous data (Pinheiro et al., 2013), since we noted -- and discussed carefully in the Discussion that calcium-dependent priming is still present in Doc2B KO cells, probably because of redundant processes/proteins (as the reviewer mentions), which can be overridden by overexpression of Doc2B DN. When comparing to data obtained in synapses, it is worth remembering that the vesicles we study here (large dense-core vesicles) are different from synaptic vesicles, and there is nothing surprising in having different functions of the protein in the two (very) different systems. Also, the groups studying synaptic vesicles cannot agree as to the function of Doc2B in asynchronous release. Nevertheless, we think the data might be reconciled, since priming in chromaffin cells is driven by SNARE-complex assembly, and Ca^2+^-dependent (due to the trafficking of Doc2B) SNARE-complex formation could very well in other systems lead to spontaneous, or even (if fast enough, which is unclear) asynchronous release.

> 2\) Previously, the authors have shown that overexpressing Doc2B increased significantly the total number of vesicles per cell as well as the number of membrane-proximal vesicles (Pinheiro et al., 2013). This raises the question, to what extent apparent changes in priming with the DN and 6A mutation are accompanied by alterations in vesicle number and whether a similar phenotype can be observed with the mutant proteins. In this context, I do not understand the authors\' statement in subsection "Doc2B supports vesicle priming as a calcium sensor": \"The DN-mutant was expressed at similar levels as WT Doc2B, and VAMP2/synaptobrevin-2 staining also showed similar levels, consistent with an unperturbed granule density in the presence of Doc2B expression ([Figure 2B-C](#fig2){ref-type="fig"}).\" The authors should clarify this point.

We have repeated the stainings, as explained above. In the process of doing this, we realized that quantification of Doc2 and Syb2 cannot be done accurately on samples stained for both proteins, because the expression and staining of Doc2 reduces the staining for Syb2, probably because of antibody interference. We have therefore performed separate stainings for Doc2 and syb2, in an attempt to solve this question. However, this didn't change the conclusion. We can only speculate why there is a difference between the EM and the immunostaining. These are very different measures, and there are plenty of reasons these measures could turn out different. In the EM the levels of proteins were not quantified; In Immunostaining we did not quantify granules, only overall syb2-intensity. Thus, formally one possibility is that the total syb2 content is distributed between more granules after overexpression, although because these measurements were done several years apart by different people, we would not be comfortable making such a conclusion at the present time. We now pointed out this possible discrepancy in the Discussion section.

> 3\) The most prominent phenotype in Doc2B KO seems to be the enhanced sustained release under prolonged elevation of \[Ca^2+^\]i. This action of Doc2B is dependent on its MID-domain ([Figure 8C](#fig8){ref-type="fig"}) but curiously not on its interaction with Munc 13-2 ([Figure 1D](#fig1){ref-type="fig"}). The authors hypothesized a secondary function of Doc2B that blocks interactions with CAPS-proteins leading to inhibition of sustained release. While intriguing, the authors provide no evidence for an interaction between Doc2B MID domain and CAPS-protein. Furthermore, functional studies of Doc2B action in CAPS KO are required to draw such conclusions, in absence of which the readers are left with rather incomplete understanding of the inhibitory action of Doc2B. Thus, it might be helpful to study the Doc2B-CAPS interactions to better clarify the mechanism of inhibitory Doc2B function in chromaffin cells.

We agree, studying the Doc2B-CAPS interaction directly would certainly be helpful. However, repeating the experiments in CAPS DKO cells has not been possible, because we currently don't have CAPS DKO mice available in the laboratory. We have tried to make it clearer in our text that we are discussing the possibilities; we are not drawing a conclusion.

> 4\) It remains unclear why specifically the RRP but not the IRP is altered with Doc2B DN mutant expression.

The IRP is larger on average, but it is far from significant. We now discuss this. The point is that the IRP is a subpool of the RRP, consisting of RRP-vesicles that are close to Ca^2+^-channels. Therefore, there are more factors involved in making an IRP-vesicle than a RRP-vesicle. Most likely another factor (number of Ca^2+^-channels?) is limiting for the IRP-vesicles.

[^1]: Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
